Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Clinical Microbiology Reviews
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Latest Articles
    • COVID-19 Special Collection
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Ethics Resources and Policies
  • About the Journal
    • About CMR
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Review

Clinical Significance of Enteric Protozoa in the Immunosuppressed Human Population

D. Stark, J. L. N. Barratt, S. van Hal, D. Marriott, J. Harkness, J. T. Ellis
D. Stark
1Division of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
2Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, and Department of Medical and Molecular Biosciences, Broadway, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dstark@stvincents.com.au
J. L. N. Barratt
1Division of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
2Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, and Department of Medical and Molecular Biosciences, Broadway, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. van Hal
3Microbiology and Infectious Diseases Department, Liverpool Hospital, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Marriott
1Division of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
2Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, and Department of Medical and Molecular Biosciences, Broadway, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Harkness
1Division of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
2Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, and Department of Medical and Molecular Biosciences, Broadway, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. T. Ellis
2Institute for the Biotechnology of Infectious Diseases, University of Technology Sydney, and Department of Medical and Molecular Biosciences, Broadway, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/CMR.00017-09
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

SUMMARY

SUMMARY Globally, the number of immunosuppressed people increases each year, with the human immunodeficiency virus (HIV) pandemic continuing to spread unabated in many parts of the world. Immunosuppression may also occur in malnourished persons, patients undergoing chemotherapy for malignancy, and those receiving immunosuppressive therapy. Components of the immune system can be functionally or genetically abnormal as a result of acquired (e.g., caused by HIV infection, lymphoma, or high-dose steroids or other immunosuppressive medications) or congenital illnesses, with more than 120 congenital immunodeficiencies described to date that either affect humoral immunity or compromise T-cell function. All individuals affected by immunosuppression are at risk of infection by opportunistic parasites (such as the microsporidia) as well as those more commonly associated with gastrointestinal disease (such as Giardia). The outcome of infection by enteric protozoan parasites is dependent on absolute CD4+ cell counts, with lower counts being associated with more severe disease, more atypical disease, and a greater risk of disseminated disease. This review summarizes our current state of knowledge on the significance of enteric parasitic protozoa as a cause of disease in immunosuppressed persons and also provides guidance on recent advances in diagnosis and therapy for the control of these important parasites.

INTRODUCTION

Parasitic diseases continue to cause significant morbidity and mortality throughout the world irrespective of the patient's immune status. It is estimated that there are approximately 340 parasite species capable of infecting humans, with the majority of the 3 billion people currently infected residing in developing regions of the world (99). Enteric protozoan parasites remain the most commonly encountered parasitic diseases and continue to cause significant morbidity and mortality.

Risk factors for acquisition of parasitic infections are the same in both immunocompetent (IC) and immunosuppressed (IS) individuals. What, then, is the role of the immune system in parasitic infections? Through local and systemic responses, the immune system plays an integral part in modifying the establishment of infection, controlling disease once it is established, limiting the severity and dissemination of the disease, and assisting in clearance or control of the parasite. Thus, IS hosts are more likely to acquire infection after exposure, have more severe disease once the infection is established, have disseminated infection rather than localized infection, and be unable to clear parasites with chronic carriage states. These all lead to, and account for, the greater morbidity and mortality in these patients. However, the majority of IS individuals do not differ from IC hosts in their presentation, with the major determinants of clinical severity and outcome of parasitic infection in IS patients being the degree of immune deficiency. Furthermore, with immune reconstitution through effective therapy or withdrawal of immunosuppressive agents, these patients are more likely to behave like IC hosts.

The number of IS individuals worldwide continues to increase each year as the human immunodeficiency virus (HIV) pandemic continues to spread unabated in many parts of the world, with an estimated 14,000 new infections occurring daily (19). What compounds this problem is that the majority of these new infections continue to occur in regions of the world where access to active therapy is limited and thus patients progress to profound immunosuppression (i.e., AIDS). In contrast, in more developed nations the numbers of IS individuals continue to increase as a result of medical interventions with more aggressive immunosuppressive therapies for immune-mediated disorders and hematopoietic and solid organ transplants, with approximately 1 million transplants performed annually (17).

A summary of studies reporting the worldwide prevalence of pathogenic enteric protozoa in HIV-infected persons is given in Table 1, and treatment options for enteric protozoal infections are listed in Table 2. Examples of stained enteric protozoa are shown in Fig. 1.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Photomicrographs of enteric protozoa stained with a modified iron-hematoxylin stain (incorporating a carbol fuschin staining step). (A) Cyclospora oocysts; (B) Cryptosporidium oocysts; (C) Dientamoeba fragilis binucleated trophozoite; (D) Dientamoeba fragilis uninucleated trophozoite; (E) Entamoeba histolytica cysts; (F) Entamoeba histolytica trophozoite; (G) Giardia cysts; (H) Giardia trophozoites. Bars represent 10 μm.

View this table:
  • View inline
  • View popup
TABLE 1.

Worldwide prevalence of pathogenic enteric protozoa in HIV-infected persons

View this table:
  • View inline
  • View popup
TABLE 2.

Treatment options for infections with enteric protozoa

IMMUNITY

The immune system can simplistically be divided into three components, namely, nonspecific immunity (e.g., skin and other mucosal barriers), the innate immune system (soluble factors and cells), and the adaptive immune system. The innate system is limited to pattern recognition immune responses based on a diverse array of sensors (e.g., Toll-like receptors or complement) which detect invading pathogens. In contrast, the adaptive immune system is able to undergo maturation. This is represented by increased affinity antibody production (immunoglobulin G [IgG] as opposed to initial IgM antibodies) and cell-mediated immunity with T-cell memory. Most pathogens have developed ways of evading the protection provided by the immune system. Thus, infection and/or persistent infection/carriage is established by the interplay between the host (immune system) and the pathogen. In the IS patient, changes often occur in favor of the pathogen. The advantage to the pathogen depends on the component of the immune system that is defective. Any component of the immune system can be functionally or genetically abnormal as a result of acquired (e.g., through HIV infection, lymphomas, or high-dose steroids or other immune-suppressive medications) or congenital illnesses, with more than 120 congenital immunodeficiencies described to date that either affect humoral immunity or compromise T-cell function (19). Immunosuppression may also occur in malnourished persons, patients undergoing chemotherapy for malignancy, and those receiving immunosuppressive therapy. However, for parasitic infections, cell-mediated (T-cell) abnormalities predominate. These patients tend to have an increased risk of acquiring common pathogens (e.g., cryptosproridia) with delayed coccidian clearance. With profound cell-mediated defects, reactivation of previously controlled pathogens (e.g., toxoplasmas) can occur. In addition, these patients are at risk of infection by “nonpathogenic” parasites (those that do not cause disease in normal hosts). With reconstitution of the cell-mediated immunity, the risk of parasitic infections reverts to that for a normal host.

HIV infection is the most common immunodeficiency state worldwide, with the hallmark of infection being depletion of CD4+ T lymphocytes, essential components of the cell-mediated immune system. After acquisition of HIV through genital secretions, the virus infects local macrophages using the CD4 receptor to mediate cell entry. These cells are transported to local lymph nodes, and viral replication commences. This is followed 1 to 3 weeks later with a seroconversion syndrome similar to a glandular fever-like illness, characterized by high viral replication and a decline in CD4+ T-cell counts. Both cellular and humoral responses ensue, which reduce the viremia, and the CD4+ T-cell count reverts to normal. This is followed by an asymptomatic phase lasting from 1 to 15 years or longer, which is characterized by viral replication and variable CD4+ cell loss of approximately 25 to 60 cells/μl per year. Once the CD4+ cell count drops below 200 cells/μl, patients are considered to have developed AIDS, with the risk of an AIDS-defining illness or opportunistic infection significantly increasing.

Developing an infection with enteric protozoan parasites is dependent on absolute CD4+ cell counts, with lower counts associated with more severe disease, more atypical disease, and a greater risk of disseminated disease (16, 36, 207, 237, 280). In addition, at counts of less than 200 (i.e., profound immunosuppression), HIV-infected patients are at risk from specific opportunistic protozoan pathogens which are usually unable to establish infection in IC hosts.

OPPORTUNISTIC INFECTIONS

Opportunistic infections are generally restricted to severely IS individuals and are considered AIDS-defining illnesses in HIV-infected patients, as they almost always occur when the CD4+ T-cell count falls below 200 cells/μl. Furthermore, with effective therapy and immune reconstitution, i.e., a rise of CD4+ T cells to above 200 cells/μl, the risk of these infections virtually disappears.

Cyclospora Cyclospora cayetanensis is a coccidian protozoan most commonly found in developing regions of the world. However outbreaks of cyclosporiasis have been reported from North America (137, 138, 181) and Europe (76). The sources of infection in all these cases were traced to vegetables imported from areas of endemicity. Humans are the only known host for this parasite (99). Infection is via the fecal-oral route, though oocysts are not infective immediately after excretion in the feces and require sporulation in the environment to become infective.

Generally patients present with a rapid-onset, self-limiting diarrhea (178). With progressive immune suppression (CD4+ T cell counts of <200 cells/μl in HIV-infected individuals) prolonged carriage occurs, resulting in frequent severe relapses which may last from 4 to 7 weeks (11, 90, 139). These recurrences in turn result in severe malnutrition and significant morbidity and mortality in HIV-coinfected patients (201).

Episodes of diarrhea associated with C. cayetanensis infections have also been documented in other IS hosts, with cases of prolonged diarrhea in patients with compensated idiopathic hepatic cirrhosis, protein energy malnutrition, Hodgkin's lymphoma, and acute lymphoblastic leukemia being described (133, 215, 287).

Disseminated infections are uncommon, with several described cases involving the biliary tract in HIV-infected individuals (112, 291). Diagnosis was confirmed by histological confirmation of C. cayetanensis in the gallbladder epithelium following cholecystectomy for acalculous cholecystitis (291). Although C. cayetanensis oocysts have been observed in respiratory samples, it remains unclear whether these caused pulmonary disease, as no respiratory tissue samples were obtained (109).

Diagnosis of Cyclospora oocysts may be problematic, as most laboratories fail to recognize them in direct fecal smears. Special stains such as modified acid-fast auramine or modified iron-hematoxylin are usually required for definitive diagnosis. Other methods used are autofluorescence under UV epifluorescence (99) and DNA amplification by PCR (171). Histopathological examination of jejunal biopsy specimens from infected individuals showed mild to moderate acute inflammation of the lamina propria and surface epithelial disarray.

Cyclosporosis in patients can be treated effectively with a 10-day course of trimethoprim-sulfamethoxazole. Maintenance therapy with either trimethoprim-sulfamethoxazole or sulfadoxine-pyrimethamine is required to prevent recurrent disease (275). Alternatives include nitazoxanide (a new thiazolide antiparasitic agent), combination therapy with both pyrimethamine and leucovorin, or ciprofloxacin (295).

Data on the immune response to C. cayetanensis and mechanisms of immunity to this pathogen and how these relate to various immune deficiencies are lacking. However, previous exposure to Cyclospora may confer some resistance against challenge infection (98).

Cryptosporidium Cryptosporidium species have a worldwide distribution, and the ability to infect a large range of vertebrate hosts (208, 212, 223, 236, 263). Cryptosporidium parvum and Cryptosporidium hominis are the species most commonly associated with human cryptosporidiosis (149), though infections with other species such as Cryptosporidium felis and Cryptosporidium meleagridis (121, 224) have been reported, particularly in IS patients (149, 198). Infection is via the fecal-oral route.

Studies from London and Nairobi demonstrate that cryptosporidiosis remains the most common opportunistic enteric protozoal disease encountered in IS HIV-infected patients (78, 203). This is supported by a recent prospective, comparative study comparing the prevalences of enteric protozoa among HIV-positive and -negative men in Australia (254). A total of 1,868 patients submitted stool specimens over a 36-month period for examination for the presence of enteric parasites. In this study C. parvum cases occurred exclusively in HIV-positive patients. Other IS groups at significant risk of severe cryptosporidiosis include those diagnosed with non-Hodgkin's lymphoma, leukemia, lymphoproliferative disease, or protein energy malnutrition (51, 133, 205, 215). Patients receiving immunosuppressive drugs for organ transplants or cancers are also at risk of prolonged, potentially life-threatening persistent diarrhea (67, 140, 238), as are IS patients undergoing hemodialysis (244). Cryptosporidium infection with serious clinical symptoms has also been observed in IS patients with hyper-IgM syndrome and primary CD4 lymphopenia (286). Cryptosporidium parvum infections have also been reported in transplant patients undergoing immunosuppressive therapy. One case study reports C. parvum-related sclerosing cholangitis in a 40-year-old renal transplant patient. After reduction of immunosuppression, C. parvum was cleared from her stool, with a marked improvement in diarrhea and general health (1).

Patients that are not IS tend to present with a self-limiting diarrhea, which may last for several weeks to months even in IC individuals. The highest burden of disease occurs in children under 5 years of age (2). Infection in the IS individual is usually associated with chronic diarrhea and wasting and can be life threatening (2, 197, 203). Disseminated infection has been described, predominantly involving the biliary tract with cases of ascending cholangitis (24, 29, 49, 288). Other manifestations include pulmonary cryptosporidiosis (163, 218). These infections may occur in the absence of gastrointestinal involvement (218).

Laboratory diagnosis of cryptosporidiosis traditionally relies on special staining techniques, such as modified acid-fast, Kinyoun's, and Giemsa stains, as oocysts are difficult to detect using basic light microscopy (99). Other alternative diagnostic techniques have also been employed. Several commercial companies have developed rapid diagnostic tests that are simple to perform and can be completed in less time than traditional methods for detecting Cryptosporidium; these rapid tests include lateral-flow immunoassays, immunochromatograhic assays, and direct fluorescent-antibody tests (151) The use of enzyme-linked immunosorbent assay (ELISA) for the detection of Cryptosporidium antigen in stools has been described (147), and PCR assays have been developed for the specific detection of Cryptosporidium species in stools. A TaqMan PCR assay targeting the 18S ribosomal DNA (rDNA) has allowed sensitive detection of Cryptosporidium species (155). Various other PCR assays for the detection of Cryptosporidium species in stool specimens have also been developed (18, 107, 136, 293). While being more expensive and time-consuming, PCR and ELISA have shown superior sensitivity for the detection of Cryptosporidium species compared to conventional staining and microscopy (158, 199).

Based upon the paucity of evidence, the effectiveness of any therapeutic agent in the treatment of cryptosporidiosis has yet to be confirmed. However, the drugs paromomycin, azithromycin (218), and nitazoxanide (249) have been used to treat cryptosporidiosis in HIV-infected patients and have been shown to reduce the parasite load. Resolution of cryptosporidiosis can be maintained with effective highly active antiretroviral therapy (HAART) (191, 218, 242, 292). There is also evidence to suggest that some antiretroviral compounds used in HAART may have a direct inhibitory effect on Cryptosporidium (197).

Both humoral and cellular immune mechanisms appear to be necessary for protection against Cryptosporidium. The exacerbation of disease by immune suppression reflects the role of the immune system in controlling replication of the organism. IS patients with cryptosporidiosis fail to develop a significant serological response to the organism (184); in contrast, seroepidemiological studies have indicated that between 30 and 80% of IC patients will elicit an antibody response (26). Reports of chronic cryptosporidiosis in children with congenital Ig deficiency but intact cellular immunity highlight the importance of antibodies in the immune response against cryptosporidium (172). Murine models have shown that gamma interferon mediates an important protective innate response against Cryptosporidium infection (188). Studies suggest that CD4+ cells in the gut epithelium also play a role in controlling infection, along with Th1 and Th2 cytokine production (187, 267).

Isospora belli Isospora belli is a coccidian parasite that has a global distribution limited to mainly tropical regions in developing countries where it is endemic (especially Africa, the Middle East, and South America). The parasite invades the intestinal epithelium, where it completes its life cycle in the cytoplasm of the enterocyst (234). Unsporulated oocysts are excreted in feces and mature outside the host, where they develop into infective sporulated oocysts. Infection is then acquired through ingestion of these infective oocysts. Immunodeficiency was shown to increase the susceptibility to infection with I. belli (117), which accounted for up to 20% of cases of diarrhea in AIDS patients (46, 65).

The parasite may cause acute self-limiting diarrhea, fever, and abdominal pain that usually resolves spontaneously in a normal host. In severely IS patients, severe chronic diarrhea is often reported and has been associated with fulminant diarrhea leading to a wasting syndrome and sometimes death in AIDS patients (46).

Diarrhea associated with I. belli infections has also been reported in patients with other immunosuppressive diseases, such as lymphoblastic leukemia (148, 283), adult T-cell leukemia (115, 159), Hodgkin's disease (225), non-Hodgkin's lymphoma (234), lymphoproliferative disorders (159, 214), and renal transplant recipients (169), and in a liver transplant patient with chronic diarrhea (15). Patients with malabsorption syndrome, particularly malnourished children, are also at increased risk of chronic isosporiasis (21, 168).

As with other opportunistic protozoal pathogens, clinical manifestations are dependent on the balance between the immune system and the virulence of the organism, with chronic carriage states (“latency”) and clinically symptomatic reactivation during periods of severe immunodeficiency (152), as reported for a recent case of reactivation 8 years following acquisition (234).

Diagnosis is by direct visualization of the oocyst in feces; however, for some patients microscopic examination of stool samples may remain negative, even in cases of severe diarrhea (65) Therefore, a mucosal biopsy may be required for a definitive diagnosis. Detection of I. belli by PCR has been used as an additional diagnostic tool in clinical laboratories. Conventional PCR using primers based on 18S rDNA sequences shows excellent sensitivity and specificity (202). Recently, a real-time PCR targeting the internal transcribed spacer 2 region of the rRNA gene for the detection of Isospora belli DNA in fecal samples was developed. This real-time assay achieved 100% specificity and sensitivity (266).

Isospora infection responds promptly to antimicrobial therapy. Co-trimoxazole, sulfadiazine, and pyrimethamine have all been used successfully to treat isosporiasis (65, 219, 283). A number of randomized control trials conducted in areas of endemicity have shown a very high efficacy of co-trimoxazole against I. belli (275), with a 7- to 10-day course usually being efficacious in treating the infection (234). Maintenance or secondary prophylaxis should be used to prevent relapses (275).

Once again, there are limited data in the scientific literature in regard to the mechanisms of immunity to this pathogen, and it is evident that more research is needed in this area.

MicrosporidiaThe term microsporidia is used as general nomenclature for the obligate intracellular parasites belonging to the phylum Microsporidia. Microsporidia were originally classified as protozoa, though it has been recently suggested that they are more closely related to fungi and as such should no longer be considered protozoa (135). However, as the precise relationship between the microsporidia and fungi is yet to be defined, microsporidia are included here as protozoa.

Thirteen hundred species of microsporidia belonging to 160 genera and infecting a wide range of vertebrate and invertebrate hosts have been described. Fourteen microsporidian species have been identified as human pathogens: Anncalia algerae, Anncalia connori, Anncalia vesicularum, Encephalitozoon cuniculi, Encephalitozoon hellem, Encephalitozoon intestinalis (syn. Septata intestinalis), Enterocytozoon bieneusi, Microsporidium ceylonensis, Microsporidium africanum, Nosema ocularum, Pleistophora ronneafiei, Trachipleistophora hominis, Trachipleistophora anthropophthera, and Vittaforma corneae. Of these, E. bieneusi and E. intestinalis are the two most common causes of human enteric disease.

Microsporidia are recognized as opportunistic infectious agents worldwide in both developed and developing countries. Human microsporidiosis represents an important disease, occurring mainly but not exclusively in severely immunocompromised patients with AIDS. A recent study examined a total of 893 fecal specimens from hospitalized patients for microsporidia using a modification of the Gram-chromotrope stain technique. One hundred sixteen patients (13.0%) were positive for microsporidia, and approximately one-third of the patients were IC individuals. Microsporidiosis was commonly observed in children aged 0 to 6 years (26.4%) and adults aged ≥31 years (57.2%). Among the IS group, microsporidia were observed to be more prevalent in patients with hematological malignancy or a combination of malignancy and diabetes mellitus (210). What role microsporidia play in causing gastrointestinal symptoms in IC populations is unclear. However, another recent study found that microsporidia were more prevalent in IC individuals than in HIV-infected patients, with none of the IC group displaying gastrointestinal symptoms (209).

The mode of transmission for the various microsporidia remains obscure. It is accepted that infection occurs via the fecal-oral route for intestinal microsporidia such as E. bieneusi and E. intestinalis, as spores of these species are shed in the feces, but they can also often be shed in the urine from disseminated infections of the kidney. This is supported by the finding of E. bieneusi and E. intestinalis spores in recreational bathing water alongside oocysts of other enteric pathogens (94, 95, 114).

Enterocytozoon bieneusi is the most common microsporidian in humans (130) and the second most prevalent cause of diarrhea in IC patients, after Cryptosporidium (32). However, in countries with access to HAART, the prevalence of microsporidial infections has declined (105). In a study from Australia, van Hal et al. (273) found that the total incidence of intestinal microsporidiosis in HIV-infected patients declined from 11% in 1995 to 0% from 2004 onwards. These dramatic changes have been attributed to restoration of cell-mediated immunity and possibly secondary to the direct antiparasitic activity of some components of HAART (i.e., protease inhibitors) (228). In contrast, in developing countries with limited access to HAART, the incidence of microsporidiosis remains high (33).

The clinical manifestations of microsporidiosis are very diverse and vary according to the causal species, with diarrhea being the most common. In the case of E. bieneusi infection, the disease is usually confined to the gastrointestinal tract, though disseminated infection can occur. In HIV patients with E. bieneusi infection, chronic diarrhea associated with wasting syndromes and cachexia are common (32, 130). Dissemination to the hepatobilary system with cholangitis (29, 226), to the maxillary sinus with invasive sinusitis (131, 272), and to the respiratory system with pulmonary infections (28, 66) have all been reported for E. bieneusi/HIV coinfections. Intestinal disease resulting from E. bieneusi infection has also been reported in heart-lung, liver, and renal transplant recipients undergoing immunosuppressive therapy (110, 116, 190, 231, 248).

Encephalitozoon spp. are the second most common microsporidia in humans and the most common cause of disseminated microsporidiosis (130, 153, 164, 268, 278, 279). There are three species within this genus that are known to cause human disease: E. cuniculi, E. hellem, and E. intestinalis. While E. intestinalis can infect most tissues, this species is usually associated with enteric disease (14, 81).

Traditionally, light microscopy based on modified trichrome stains (e.g., Ryan's stain) has been used by most laboratories for the diagnosis of enteric microsporidiosis (70). Immunofluorescence tests using the chitin binding fluorochromes Uvitex 2B, Fungifluor, calcofluor white, and Fungiqual A are also available and offer a sensitive and rapid method for detecting microsporidial spores in stool, intestinal fluid, biopsy imprint, and tissue specimens, even from archived material (5, 58, 87, 97, 200, 294) Molecularly based PCR assays (63, 77, 96) are also available for the diagnosis of E. bieneusi and E. intestinalis infection. The advantage of molecular testing over microscopic methods is that it allows for determination of the species of microsporidia. A comparison of PCR and an immunofluorescent-antibody test (IFAT) for the detection of E. bieneusi and E. intestinalis found that the two techniques had similar sensitivities, though IFAT was cheaper and more rapid (6). However, there are currently no commercially available or FDA-approved IFAT kits. Staining of tissue sections by the Warthin-Starry staining method was assessed as an effective diagnostic tool for the microscopic detection of microsporidia and demonstrated better diagnostic capabilities than the hematoxylin and eosin stain (88, 89).

Management of microsporidial infection most often includes oral treatment with the drug albendazole (23, 52, 85, 105, 193). Albendazole has demonstrated good antimicrosporidial activity against Encephalitozoon spp., particularly E. hellem (69, 71) (in vivo and in vitro), though it is only partially active against E. bieneusi (57, 73, 85, 105, 157, 162, 193). The drug nitazoxanide has demonstrated activity against E. bieneusi, with the symptoms of one patient receiving nitazoxanide therapy resolving in the absence of antiretroviral therapy (22). The drug fumagillin has also demonstrated good anti-Enterocytozoon bieneusi activity (40, 57, 195), although various adverse side effects have been documented (56, 141, 194, 195). The drug furazolidone has also demonstrated a degree of anti-Enterocytozoon activity (74). As with most opportunistic infections, HAART plays a key role in eradicating microsporidia in HIV-infected patients (105), and effective HAART is likely to reduce the incidence of microsporidial infections in the future.

Cell-mediated immunity appears to be critical for protection against the microsporidia. An effective Th1 cytokine response is important in the immune response to infection. However, the role of humoral immune responses in human microsporidial infections is yet to be fully elucidated (72).

OTHER PATHOGENIC ENTERIC PARASITES

Infections with the following pathogenic enteric parasites generally occur in both IC and IS patients. Although greater rates of carriage of some of these pathogens (i.e., Entamoeba histolytica) are associated with HIV-infected patients, this probably reflects the higher opportunity acquisition risk secondary to various sexual practices rather than the immune deficiency per se.

Blastocystis spp. Blastocystis spp. are enteric unicellular parasites that are the most frequently reported parasite in human fecal samples (261). Although traditionally classified as a protozoan parasite, recently, due to new molecular techniques, Blastocystis has been shown to be closely related to the stramenopiles. However, due to it being nonmotile and not possessing flagella, in contrast to other stramenopiles, it has been placed in a new class, class Blastocystea, in the subphylum Opalinata, infrakingdom Heterokonta, subkingdom Chromobiota, kingdom Chromista (45).

Blastocystis exhibits extensive genetic diversity, and this has been documented using numerous molecular techniques. Currently there are at least nine subtypes (genotypes) within Blastocystis. Recent studies have shown that no group exclusive to humans exists and that all clades have been detected in human stool (222). Consequently, human isolates of Blastocystis that were commonly referred to as Blastocystis hominis should be called Blastocystis spp. due to there not being a single subtype specific to humans.

Laboratory diagnosis of Blastocystis relies on several methods for identification, including light microscopy of fresh samples from wet preparations and concentrates, permanently stained fixed fecal smears, culture, and molecular techniques (55, 260, 261).

There is still much controversy surrounding Blastocystis and its pathogenicity in humans. There are conflicting reports in the scientific literature, where many authors view Blastocystis as a pathogen, (10, 41, 176, 177) while many other reports doubt the role of Blastocystis in human infection (175, 270). The most common symptoms associated with this parasite are diarrhea, abdominal pains, and vomiting. As no recognized animal model exists for Blastocystis, Koch's postulates are unable to be fulfilled in order to confirm or exclude the pathogenic nature of this organism. While the organism has a global distribution, the prevalence is higher in developing countries (261). Acquisition of the organism is thought to occur as a result of frequent animal-human, human-human, and human-animal transmission, with reports of carriage of Blastocystis in mammals, birds, amphibians, and even insects (264, 265).

What role Blastocystis plays in gastrointestinal disease in IS hosts is also unclear. There have been several studies of the prevalence of intestinal parasites in HIV-infected patients, with most finding higher rates of Blastocystis carriage. Several studies from Africa showed Blastocystis infection to be at a higher rate in HIV-positive patients than in negative controls. A study in Senegal found Blastocystis only in HIV-infected patients, with all but one suffering from diarrhea and with no other pathogens found in the samples. This study suggested that Blastocystis may be considered an opportunistic parasite (104). Another African study in an Ethiopian teaching hospital found there to be an incidence of Blastocystis infection of 14.1% in HIV/AIDS patients. There were no statistically significant differences in the prevalence of parasites among cases and controls except for Blastocystis, which was significantly higher in HIV/AIDS patients, which shows that it may be a possible pathogen in immunocompromised patients (122). A study in Iran showed that the occurrence of parasites in HIV-infected patients was not as high as seen in African countries, with an infection rate of only 18.4%. Of the parasites seen in that study, though, Blastocystis was the second most prevalent at 4.4%, with most of these cases being seen in patients with diarrhea (289). There are also insufficient data on the immunology of the parasite and the interactions with IS hosts.

Dientamoeba fragilis Dientamoeba fragilis is a trichomonad parasite. Humans are probably the definitive host of this parasite even though D. fragilis trophozoites have been reported in nonhuman primates, including macaques (132, 167), baboons (204), and gorillas (255).

There is little understanding of the pathogenesis and pathology resulting from D. fragilis infection, and understanding is further hampered by the lack of a suitable animal model (75, 161, 166). However, acute and chronic diarrhea with associated abdominal pain has been documented in IC children and adults (61, 253, 285).

The impact of immune deficiency on D. fragilis infection and disease remains unclear. A study from Argentina found higher rates of D. fragilis infections in IS patients, in contrast to an Australian study, which found no difference in carriage rates in HIV-infected patients and the general population (189, 254). Clearly, further study of all aspects of this infection and in all patient groups is warranted.

Diagnosis of D. fragilis is based on prompt fixation and permanent staining, as trophozoites degenerate within hours of being passed and demonstration of the characteristic nuclear structure is achieved by use of permanently stained preparations only (284). However, as many laboratories do not routinely perform permanent staining, the incidence of D. fragilis is likely to be underestimated. Newer molecular techniques, such as conventional and real-time PCR, targeting the 18S rDNA have been developed (251-253, 257).

Multiple differing antimicrobial agents have been used for treatment of D. fragilis with varying success. These include doxycycline, iodoquinol, metronidazole, and secnidazole (25, 108, 150, 230). However, there is no general consensus on what is best practice in treating D. fragilis infections. There are also no data available on the mechanisms of immunity for this parasite.

Entamoeba histolytica Entamoeba histolytica is a nonflagellated amoeboid protozoan parasite. The genus Entamoeba includes six species (E. histolytica, Entamoeba dispar, Entamoeba moshkovskii, Entamoeba polecki, Entamoeba coli, and Entamoeba hartmanni) that are capable of infecting the intestinal lumen of humans. All these species are considered commensal organisms and rarely (if ever) cause intestinal disease in humans, with the exception of the pathogenic E. histolytica, for which humans are the primary reservoir (258). Entamoeba histolytica is an invasive pathogen and the causative agent of amoebiasis, with approximately 50 million cases acquired annually in the developing world (274). What role E. moshkovkii plays in human infections is yet to be adequately defined, most likely in part due to diagnostic confusion with E. histolytica and E. dispar. Although previous studies have not shown any association between E. moshkovskii in clinical samples and disease (54), recent studies have reported E. moshkovskii as an enteropathogen in patients presenting with gastrointestinal symptoms (92, 93, 221). There have also been no adequate studies examining the pathogenic potential of this organism in IS groups, and it is clear that further study is needed to assess the true pathogenicity of this organism.

The factors that control the pathogenesis of E. histolytica are not completely understood. However, key features are the ability of the organism to lyse host cells and cause tissue destruction, with induced immune responses occurring in invasive disease (3). Entamoeba histolytica acquisition is via the fecal-oral route. In confined populations (e.g., men who have sex with men [MSM] visiting sex-on-premises venues), carriage rates are significantly higher than in the general population once the organism has been established secondary to various oral-anal sexual practices (173, 254, 274). As the risks for HIV acquisition and parasite acquisition in these environments overlap, apparent associations between E. histolytica and immunosuppression exist. However, in an Australian study Entamoeba infection was found to be more prevalent in HIV-negative than in HIV-positive MSM with diarrhea. In the United States E. histolytica rates in AIDS patients remain low, with amoebiasis being diagnosed more frequently in individuals exposed to HIV through male-male intercourse (182). Thus, it is probable that HIV-positive individuals are no more susceptible to gastrointestinal symptoms than HIV-negative individuals.

Following an incubation period that can vary greatly, ranging from days to years, individuals infected with E. histolytica present with symptoms of abdominal pain, tenderness, and diarrhea with >10 bowel movements/day, corresponding with colitis and ulcerative disease on histopathological examination. Bowel complications occur in 1 to 4% of patients. Invasive or extraintestinal disease is uncommon and may be present in 0.1 to 1% of symptomatic patients, with the liver being the most common site involved (>50%) (259). The lungs are the second most common site of invasive amoebiasis (245). Invasive amoebiasis involving the heart (59, 111, 245), brain (20, 143, 277), and genitourinary tract (38, 183, 217) has also been reported. Generally, when clinical symptoms develop they are limited to the gastrointestinal tract. However, the likelihood of developing invasive amoebiasis is increased in the presence of HIV infection (144-146, 245), with higher rates of amoebic colitis (144, 213) and amoebic liver abscesses (35, 142, 160) reported. Furthermore, seroprevalence studies, which are considered a sensitive marker of previous invasion, suggest that immunosuppression increases the risk of disseminated disease, with significantly higher rates of antibody positivity in HIV-positive patients (50, 269).

Entamoeba dispar, the usually free-living (occasionally pathogenic) Entamoeba moshkovskii, and E. histolytica are morphologically identical, though genetic differences have confirmed the separation of these three as independent species (62, 68, 250). Due to this conserved morphology, stained smears of stool specimens are insufficient for differentiation of these species. Staining of fixed fecal smears with iron-hematoxylin or Ziehl-Neelsen stain (47, 154) can determine the presence of the Entamoeba histolytica/E.dispar/E.moshkovskii complex within a stool specimen, while other techniques such as PCR or ELISA must be employed for differentiation. A number of PCR assays are available for detection and/or differentiation of Entamoeba species (62, 127, 239). A unique approach to diagnosis of E. histolytica infection is described by Britten et al. (37), which makes use of DNA probes conjugated to an antibody-detectable protein tag. Immunological assays are also useful and often employed. Commercial antigen capture and antibody-detecting ELISA kits are also available (34, 128, 129, 165), along with rapid lateral-flow cartridge tests (101). While some authors suggest that the commercial antigen capture ELISA kits are preferable to the use of PCR due to the rapidity and simplicity of these kits (84), other authors suggest that PCR is more useful than antigen capture ELISA for detection of E. histolytica in stools due to the higher sensitivities observed in PCR and the reduced chance of cross-reactivity with other Entamoeba species (256).

A number of different serological assays for the detection of E. histolytica antibodies are commercially available. Indirect hemagglutination assays, latex agglutination assays, complement fixation assays, indirect immunofluorescence assays, and ELISAs have all been developed (91). Serological testing may be helpful from a diagnostic perspective in certain situations. In patients suspected of having extraintestinal disease, serological tests are warranted; however, testing in patients with intestinal disease is normally not recommended. The serological tests are specific but have varying sensitivity depending on the presence or absence of invasive disease and the type of invasive disease. The sensitivity for serology is 100% in patients with amoebic liver abscess and 82% in those with invasive intestinal disease (91). Antibody testing to diagnose carriage or noninvasive disease is unhelpful, as the sensitivity is low at around 8% (91). Serum IgG antibodies persist for years, and antibody titers can remain high for years after successful therapy and/or eradication of the organism. This limits the usefulness of the test in areas where infection is endemic and people have been exposed to E. histolytica, due to the inability of serological tests to distinguish past from current infection (91). However, serological tests may be helpful from a diagnostic perspective in industrialized countries, where infections and exposure to E. histolytica are uncommon.

Diagnosis of invasive disease is usually based on patient symptoms (e.g., localized pain) followed by radiographic studies to identify the presence of lesions or organomegaly (245). To identify E. histolytica as the causative agent of a tissue abscess or lesion, PCR of tissue aspirates or identification of E. histolytica antigens in tissue aspirates is required (4, 220). A possible prediction of invasive disease can be made based on the level of Ig subtypes present in the circulation. One study noted that in the event of invasive disease, anti-E. histolytica IgG and IgA levels were comparatively high, while much lower anti-E. histolytica IgM and IgE antibody levels were detected (246).

Drug treatments for amoebiasis include paromomycin, diloxanide furoate, and iodoquinol. These drugs are all effective at treating luminal amoebiasis, although they are ineffective against invasive amoebiasis (85). Nitroimidazole derivatives such as metronidazole, secnidazole, tinidazole, and ornidazole are effective for treatment of invasive amoebiasis though less effective against luminal disease (85, 119). For treatment of luminal and extraintestinal amoebiasis, Farthing (85) suggests a 5-day course of metronidiazole plus a 10-day course of diloxanide furoate or a 7- to 10-day course of paromomycin for the treatment of invasive amoebiasis.

Innate immune responses are the initial mechanisms that are responsible for limiting E. histolytica infection and invasive disease. Entamoeba histolytica has been shown to evade complement-mediated lysis (232), and extracellular cysteine proteinases of E. histolytica are capable of degrading the complement anaphylatoxins C3a and C5a (233). Intestinal epithelial cells have been shown to initiate an inflammatory response to E. histolytica infection, and nuclear factor κB and proinflammatory cytokines also play a significant role in host defense (243).

Giardia intestinalis Giardia intestinalis (synonyms, “Giardialamblia” and “Giardiaduodenalis”) is a common and ubiquitous flagellated protozoan parasite with a worldwide distribution. Giardia species are parasites of mammals and other animals, including reptiles and birds (7, 42-44, 123-126). Humans become infected by ingestion of cysts, which develop into trophozoites after excystation. Infections occur in both developed and developing regions of the world (241).

An Australian study found that HIV-infected patients were as likely to have Giardia as HIV-negative MSM (254). In this study, 3% of HIV-negative MSM were infected, compared to 4.5% of HIV-positive MSM and 1.5% of the general population. This suggests that, as with other enteric parasites, sexual practices lead to higher Giardia carriages rates (83, 196).

In developing countries the burden of disease remains high in IC individuals, especially in children less than 10 years of age, with Giardia considered normal gut flora in children in developing countries (134).

After acquisition, approximately 50% of people clear Giardia without any untoward effects, 5 to 15% of people shed cysts asymptomatically, and the remainder develop an acute and/or chronic infection (7, 241). The acute infection lasts for days to weeks and is accompanied by nausea and the sudden onset of explosive, watery, foul-smelling diarrhea. The acute phase is often followed by a subacute or chronic phase. Chronic symptoms may last for years and be continuous, intermittent, sporadic, or recurrent, with episodes of diarrhea or loose stools. Between bouts of diarrhea the patient may have normal stools. However, abdominal discomfort may be continuous and independent of the alteration in bowel habits (271).

Symptoms of giardiasis in HIV-infected individuals appear to be similar to, and no more severe than, those of giardiasis in HIV-negative individuals, with asymptomatic infection occurring commonly in the presence of HIV (39, 196). With progressive immunosuppression following reduced CD4+ counts, the risk of symptomatic Giardia infections is increased (12, 79). Despite this, giardiasis is not considered a major cause of enteritis in HIV-infected patients (12, 196).

Although there is little in the scientific literature in regard to Giardia infections in IS individuals, a number of studies have shown that Giardia is more prevalent in the stools of hypogammaglobulinemic patients than in those of IC hosts (86, 235). It has also been shown that the majority (>90%) of hypogammaglobulinemic patients passing Giardia cysts are symptomatic, with chronic diarrhea (30). Symptomatic giardiasis has been observed in X-linked infantile congenital hypogammaglobulinemia (Bruton's syndrome) and also in the common variable (late-onset) acquired hypogammaglobulinemia (30). IS patients, including nephrotic syndrome children receiving corticosteroids, protein-calorie malnutrition patients, patients with cases of marasmic kwashiorkor, and lymphoma patients, were found to be significantly more at risk for Giardia infection (211).

Enzyme immunoassays, immunochromatographic assays, and direct-fluorescence assays for detection of G. intestinalis in stool have been available in the form of commercial kits for several years (113, 216, 282). These kits are commonly used in diagnostic laboratories. Compared to microscopy, the coproantigen assays are less time-consuming and easier to perform. However, conflicting data in the exist in the scientific literature in regard to the performance of these rapid assays. Some researchers have reported excellent sensitivity and specificity (48, 100-102), while others have reported the rapid tests to be generally less sensitive than conventional microscopic methods (216, 282). A number of PCR assays are also available for the detection of Giardia in stool specimens (8, 106, 120, 276). Giardia infection can also be diagnosed microscopically by identification of cysts and trophozoites in stained or unstained fecal smears. Giardia cysts and trophozoites have a unique morphology, different from that of most other protozoa, and thus can be identified by trained lab staff in a simple wet preparation of the fecal specimen.

Giardia infection can be treated with metronidiazole, quinacrine, furazolidone, paromamycin, tinidazole, nitrazoxamide, and ornidazole (13, 85, 103, 196). Albendazole has also demonstrated good antigiardial activity and therapeutic efficacy (103). Gupta et al. (119) suggest that metronidiazole is the drug of choice for treating giardiasis and advise a dosage of 15 mg/kg/day in three divided doses for 5 days or 2 g daily for 3 days.

Antigiardial host defenses are B-cell dependent, with secretory IgA antibodies playing an important role (80). T cells also appear to be important in the intestinal elimination of the organism. However, patients with marked T-cell deficiencies do not exhibit an increased susceptibility to giardiasis (281).

CONCLUSIONS

Gastrointestinal disease, such as diarrhea, abdominal pain, and irritable bowel syndrome, are common in the world's population. For example, an estimated 1.6 to 2.5 million deaths of children under 5 years old are caused by diarrhea globally (170, 180), with approximately 73% of these deaths being in just 15 developing countries (27). In addition, diarrhea is also a major cause of morbidity and death in HIV-infected individuals (227). In coming years there is likely to be an increase in the number of HIV/AIDS deaths, with worrying projections of 6.5 million deaths in 2030 and HIV/AIDS being the main burden of disease in some developing countries by 2015 (185). In developed countries the number of IS individuals continue to increase each year with more patients undergoing hematopoietic and solid organ transplants and more aggressive treatments instigated with immunosuppressive therapies. Furthermore, although diarrheal diseases may be declining due to improvements in treatment, the total population of people continues to grow, leaving diarrheal diseases remaining as a major problem, especially in the developing world. It is thus likely that the clinical significance of enteric protozoa in the IS population will continue to grow globally.

Each year, many studies of infectious diseases and their interaction with the immune system are published. Central to most of this research is a knockout mouse, which has assumed an important role in studies investigating how the immune system functions not only in response to microbes but also in other disease conditions (186, 247). Indeed, advances in our understanding of the mechanisms by which pathogens cause diarrhea have been greatly enhanced by the availability of immune-suppressed mice generated by knockout technologies (206). Unfortunately, our knowledge of the human immune system and the way it interacts with parasites is much more limited, despite the recognition that enteric parasites are commonly associated with the onset of diarrhea in IS patients. CD4 counts play an incredibly important role in the presentation of diarrhea as well as in the control of protozoa in HIV-infected individuals. For example, chronic diarrhea is typically associated with lower CD4 counts than acute diarrhea. In addition, at counts of less than 200, HIV-infected patients are at risk from specific opportunistic protozoan pathogens which are usually unable to establish infection in IC hosts (207, 280).

Advances in the diagnosis of infectious diseases occur regularly, although the first form of diagnosis of parasite infections is still by light microscopy of stool by an experienced microscopist. Commercially available fecal immunoassays now not only are widely available for the majority of enteric protozoa but also provide a cost-effective alternative to traditional diagnosis of protozoan enteric parasites. These kits are rapid and easy to use and are far more practical for most laboratories than PCR assays. A confirmatory test such as PCR may be run subsequently. Ironically, even in today's age of modern technology being available in the developed world, the cause of gastroenteritis may still go undiagnosed in about 50% of cases (9). Even in IC individuals, the presence of parasites, including D. fragilis, is normally overlooked in cases of diarrhea, as the provision of appropriate technology in diagnostic laboratories is not yet commonplace or routine. Nine parasitic protozoan species or genera (B. hominis, Cryptosporidium spp., Cyclospora spp., D. fragilis, E. histolytica, E. bieneusi, E. intestinalis, G. intestinalis, and I. belli) are recognized as a cause of gastrointestinal disease (primarily diarrhea), with three additional species (E. dispar, E. moshkovskii, and E. polecki) warranting further investigation into their role as pathogens of the human gastrointestinal track.

Several of the parasite species discussed here are zoonotic, and animals may be the reservoir and source of the parasite species. Exposure to pets and other animals is a recognized risk factor for acquisition of enteric parasites causing diarrhea (79). Infection is likely to be acquired via ingestion (fecal-oral transmission), with contaminated food or water representing the likely vehicle of transmission (64, 156). In at-risk groups, sexual practices may also represent a contributor to the transmission of parasites (254).

  • Copyright © 2009 American Society for Microbiology

REFERENCES

  1. 1.↵
    Abdo, A., J. Klassen, S. Urbanski, E. Raber, and M. G. Swain. 2003. Reversible sclerosing cholangitis secondary to cryptosporidiosis in a renal transplant patient. J. Hepatol.38:688-691.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    Abubakar, I., S. H. Aliyu, C. Arumugam, P. R. Hunter, and N. K. Usman. 2008. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst. Rev. doi:10.1002/14651858.CD004932.pub2.
    OpenUrlCrossRef
  3. 3.↵
    Ackers, J. P., and D. Mirelman. 2006. Progress in research on Entamoeba histolytica pathogenesis. Curr. Opin. Microbiol.9:367-373.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Ahmad, N., M. Khan, M. I. Hoque, R. Haque, and D. Mondol. 2007. Detection of Entamoeba histolytica DNA from liver abscess aspirate using polymerase chain reaction (PCR): a diagnostic tool for amoebic liver abscess. Bangladesh Med. Res. Counc. Bull.33:13-20.
    OpenUrlPubMed
  5. 5.↵
    Aldras, A. M., J. M. Orenstein, D. P. Kotler, J. A. Shadduck, and E. S. Didier. 1994. Detection of microsporidia by indirect immunofluorescence antibody test using polyclonal and monoclonal antibodies. J. Clin. Microbiol.32:608-612.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Alfa Cisse, O., A. Ouattara, M. Thellier, I. Accoceberry, S. Biligui, D. Minta, O. Doumbo, I. Desportes-Livage, M. A. Thera, M. Danis, and A. Datry. 2002. Evaluation of an immunofluorescent-antibody test using monoclonal antibodies directed against Enterocytozoon bieneusi and Encephalitozoon intestinalis for diagnosis of intestinal microsporidiosis in Bamako (Mali). J. Clin. Microbiol.40:1715-1718.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Ali, S. A., and D. R. Hill. 2003. Giardia intestinalis. Curr. Opin. Infect. Dis.16:453-460.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Amar, C. F., P. H. Dear, and J. McLauchlin. 2003. Detection and genotyping by real-time PCR/RFLP analyses of Giardia duodenalis from human faeces. J. Med. Microbiol.52:681-683.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Amar, C. F. L., C. L. East, J. Gray, M. Iturriza-Gomara, E. A. Maclure, and J. McLauchlin. 2007. Detection by PCR of eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English case-control Infectious Intestinal Disease Study (1993-1996). Eur. J. Clin. Microbiol. Infect. Dis.26:311-323.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Andiran, N., Z. C. Acikgoz, S. Turkay, and F. Andiran. 2006. Blastocystis hominis—an emerging and imitating cause of acute abdomen in children. J. Pediatr. Surg.41:1489-1491.
    OpenUrlCrossRefPubMed
  11. 11.↵
    Añé, M. S., F. A. N. Fernández, J. P. Avila, M. B. Bringuez, and B. V. Viamontes. 2000. Emergence of a new pathogen: Cyclospora cayetanensis in patients infected with human immunodeficiency virus. Rev. Cubana Med. Trop.52:66-69.
    OpenUrlPubMed
  12. 12.↵
    Angarano, G., P. Maggi, M. A. Di Bari, A. M. V. Larocca, P. Congedo, C. De Bari, O. Brandonisio, and F. Chiodo. 1997. Giardiasis in HIV: a possible role in patients with severe immune deficiency. Eur. J. Epidemiol.13:485-487.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Aslam, S., and D. M. Musher. 2007. Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. Future Microbiol.2:583-590.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Asmuth, D. M. 1994. Microsporidia and diarrhea in AIDS patients. Clin. Microbiol. Newsl.16:179-186.
    OpenUrlCrossRef
  15. 15.↵
    Atambay, M., M. R. Bayraktar, U. Kayabas, S. Yilmaz, and Y. Bayindir. 2007. A rare diarrheic parasite in a liver transplant patient: Isospora belli. Transplant. Proc.39:1693-1695.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Attili, S. V., A. K. Gulati, V. P. Singh, D. V. Varma, M. Rai, and S. Sundar. 2006. Diarrhea, CD4 counts and enteric infections in a hospital-based cohort of HIV-infected patients around Varanasi, India. BMC Infect. Dis.6:39.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Bachur, T. P., J. M. Vale, I. C. Coêlho, T. R. Queiroz, and C. D. S. Chaves. 2008 Enteric parasitic infections in HIV/AIDS patients before and after the highly active antiretroviral therapy. Braz. J. Infect. Dis.12:115-122.
    OpenUrlPubMed
  18. 18.↵
    Balatbat, A. B., G. W. Jordan, Y. J. Tang, and J. Silva, Jr. 1996. Detection of Cryptosporidium parvum DNA in human feces by nested PCR. J. Clin. Microbiol.34:1769-1772.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Barsoum, R. S. 2006. Parasitic infections in transplant recipients. Nat. Clin. Pract. Nephrol.2:490-503.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Becker, G. L., Jr., S. Knep, K. P. Lance, and L. Kaufman. 1980. Amebic abscess of the brain. Neurosurgery6:192-194.
    OpenUrlPubMedWeb of Science
  21. 21.↵
    Behera, B., B. R. Mirdha, G. K. Makharia, S. Bhatnagar, S. Dattagupta, and J. C. Samantaray. 2008. Parasites in patients with malabsorption syndrome: a clinical study in children and adults. Dig. Dis. Sci.53:672-679.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Bicart-See, A., P. Massip, M. D. Linas, and A. Datry. 2000. Successful treatment with nitazoxanide of Enterocytozoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob. Agents Chemother.44:167-168.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Blanshard, C., D. S. Ellis, D. G. Tovey, S. Dowell, and B. G. Gazzard. 1992. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS6:311-313.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    Bonacini, M. 1992. Hepatobiliary complications in patients with human immunodeficiency virus infection. Am. J. Med.92:404-411.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    Borody, T. J., E. F. Warren, A. Wettstein, G. Robertson, P. Recabarren, A. Fontella, K. Herdnman, and R. Surace. 2002. Eradication of Dientamoeba fragilis can resolve IBS-like symptoms. J. Gastroenterol. Hepatol.17(Suppl.):A103.
    OpenUrlCrossRef
  26. 26.↵
    Borowitz, S. M., and F. T. Saulsbury. 1991. Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin. J. Pediatr.119:593-595.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Boschi-Pinto, C., L. Velebit, and K. Shibuya. 2008. Estimating child mortality due to diarrhoea in developing countries. Bull. W. H. O.86:710-717.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Botterel, F., C. Minozzi, D. Vittecoq, and P. Bouree. 2002. Pulmonary localization of Enterocytozoon bieneusi in an AIDS patient: case report and review. J. Clin. Microbiol.40:4800-4801.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    Bouche, H., C. Housset, J. L. Dumont, F. Carnot, Y. Menu, B. Aveline, J. Belghiti, B. Boboc, S. Erlinger, P. Berthelot, and S. Pol. 1993. AIDS-related cholangitis: diagnostic features and course in 15 patients. J. Hepatol.17:34-39.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    Boyd, W. P., Jr., and B. A. Bachman. 1982. Gastrointestinal infections in the compromised host. Med. Clin. N. Am.66:743-753.
    OpenUrlPubMedWeb of Science
  31. 31.
    Brandonisio, O., P. Maggi, M. A. Panaro, S. Lisi, A. Andriola, A. Acquafredda, and G. Angarano. 1999. Intestinal protozoa in HIV-infected patients in Apulia, South Italy. Epidemiol. Infect.123:457-462.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Brasil, P., D. B. de Lima, D. D. de Paiva, M. S. Lobo, F. C. Sodre, S. P. Silva, E. V. Villela, E. J. Silva, J. M. Peralta, M. Morgado, and H. Moura. 2000. Clinical and diagnostic aspects of intestinal microsporidiosis in HIV-infected patients with chronic diarrhea in Rio de Janeiro, Brazil. Rev. Inst. Med. Trop. Sao Paulo42:299-304.
    OpenUrlPubMed
  33. 33.↵
    Breton, J., E. Bart-Delabesse, S. Biligui, A. Carbone, X. Seiller, M. Okome-Nkoumou, C. Nzamba, M. Kombila, I. Accoceberry, and M. Thellier. 2007. New highly divergent rRNA sequence among biodiverse genotypes of Enterocytozoon bieneusi strains isolated from humans in Gabon and Cameroon. J. Clin. Microbiol.45:2580-2589.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    Brewer, L. A., M. C. Denver, M. Whitney, and D. J. Eichinger. 2008. Analysis of commercial Entamoeba histolytica ELISA kits for the detection of Entamoeba invadens in reptiles. J. Zoo Wildl. Med.39:493-495.
    OpenUrlCrossRefPubMed
  35. 35.↵
    Brindicci, G., C. Picciarelli, L. Fumarola, S. Carbonara, F. Stano, E. Ciraci, M. Gramiccia, A. R. Sannella, M. Milella, D. De Vito, R. Monno, and L. Monno. 2006. Amoebic hepatic abscesses in an HIV-positive patient. AIDS Patient Care STDS20:606-611.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    Brink, A. K., C. Mahe, C. Watera, E. Lugada, C. Gilks, J. Whitworth, and N. French. 2002. Diarrhoea, CD4 counts and enteric infections in a community-based cohort of HIV-infected adults in Uganda. J. Infect.45:99-106.
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    Britten, D., S. M. Wilson, R. McNerney, A. H. Moody, P. L. Chiodini, and J. P. Ackers. 1997. An improved colorimetric PCR-based method for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in feces. J. Clin. Microbiol.35:1108-1111.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    Calore, E. E., N. M. Calore, and M. J. Cavaliere. 2002. Salpingitis due to Entamoeba histolytica. Braz. J. Infect. Dis.6:97-99.
    OpenUrlPubMed
  39. 39.↵
    Carcamo, C., T. Hooton, M. H. Wener, N. S. Weiss, R. Gilman, J. Arevalo, J. Carrasco, C. Seas, M. Caballero, and K. K. Holmes. 2005. Etiologies and manifestations of persistent diarrhea in adults with HIV-1 infection: a case-control study in Lima, Peru. J. Infect. Dis.191:11-19.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    Carr, A., and D. A. Cooper. 2002. Fumagillin for intestinal microsporidiosis. N. Engl. J. Med.347:1381. (Author reply, 347:1381.)
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    Carrascosa, M., J. Martinez, and J. L. Perez-Castrillon. 1996. Hemorrhagic proctosigmoiditis and Blastocystis hominis infection. Ann. Intern. Med.124:278-279.
    OpenUrlPubMedWeb of Science
  42. 42.↵
    Castro-Hermida, J. A., A. Almeid, M. Gonzalez-Warleta, J. M. Da Costa, and M. Mezo. 2006. Prevalence and preliminary genetic analysis of Giardia isolated from adult sheep in Galicia (northwest Spain). J. Eukaryot. Microbiol.53(Suppl. 1):S172-S173.
    OpenUrlCrossRefPubMed
  43. 43.
    Castro-Hermida, J. A., A. Almeida, M. Gonzalez-Warleta, J. M. Da Costa, and M. Mezo. 2006. Prevalence and preliminary genetic characterization of Cryptosporidium spp. isolated from asymptomatic heifers in Galicia (NW, Spain). J. Eukaryot. Microbiol.53(Suppl. 1):S22-S23.
    OpenUrlCrossRefPubMed
  44. 44.↵
    Castro-Hermida, J. A., A. Delafosse, I. Pors, E. Ares-Mazas, and C. Chartier. 2005. Giardia duodenalis and Cryptosporidium parvum infections in adult goats and their implications for neonatal kids. Vet. Rec.157:623-627.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    Cavalier-Smith, T. 1998. A revised six-kingdom system of life. Biol. Rev. Camb. Philos. Soc.73:203-266.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Certad, G., A. Arenas-Pinto, L. Pocaterra, G. Ferrara, J. Castro, A. Bello, and L. Nunez. 2003. Isosporiasis in Venezuelan adults infected with human immunodeficiency virus: clinical characterization. Am. J. Trop. Med. Hyg.69:217-222.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    Chacin-Bonilla, L., N. Guanipa, G. Cano, X. Raleigh, and L. Quijada. 1992. Cryptosporidiosis among patients with acquired immunodeficiency syndrome in Zulia State, Venezuela. Am. J. Trop. Med. Hyg.47:582-586.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    Chan, R., J. Chen, M. K. York, N. Setijono, R. L. Kaplan, F. Graham, and H. B. Tanowitz. 2000. Evaluation of a combination rapid immunoassay for detection of Giardia and Cryptosporidium antigens. J. Clin. Microbiol.38:393-394.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    Chen, X. M., and N. F. LaRusso. 2002. Cryptosporidiosis and the pathogenesis of AIDS-cholangiopathy. Semin. Liver Dis.22:277-289.
    OpenUrlCrossRefPubMed
  50. 50.↵
    Chen, Y., Y. Zhang, B. Yang, T. Qi, H. Lu, X. Cheng, and H. Tachibana. 2007. Seroprevalence of Entamoeba histolytica infection in HIV-infected patients in China. Am. J. Trop. Med. Hyg.77:825-828.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    Chieffi, P. P., M. A. Paschoalotti, C. S. Vergueiro, and C. S. Chiattone. 2005. Infection by Cryptosporidium sp. in immunocompromised haematological patients. Rev. Inst. Med. Trop. Sao Paulo47:301-302.
    OpenUrlPubMed
  52. 52.↵
    Chui, D. W., and R. L. Owen. 1994. AIDS and the gut. J. Gastroenterol. Hepatol.9:291-303.
    OpenUrlPubMed
  53. 53.
    Cimerman, S., B. Cimerman, and D. Salomao Lewi. 1999. Prevalence of intestinal parasitic infections in patients with acquired immunodeficiency syndrome in Brazil. Int. J. Infect. Dis.3:203-206.
    OpenUrlCrossRefPubMed
  54. 54.↵
    Clark, C. G., and L. S. Diamond. 1997. Intraspecific variation and phylogenetic relationships in the genus Entamoeba as revealed by riboprinting. J. Eukaryot. Microbiol.44:142-154.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    Clark, C. G., and L. S. Diamond. 2002. Methods for cultivation of luminal parasitic protists of clinical importance. Clin. Microbiol. Rev.15:329-341.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    Comer, E. O. 1956. Leukopenia following fumagillin therapy for amebiasis. Gastroenterology30:294-296.
    OpenUrlPubMed
  57. 57.↵
    Conteas, C. N., O. G. Berlin, L. R. Ash, and J. S. Pruthi. 2000. Therapy for human gastrointestinal microsporidiosis. Am. J. Trop. Med. Hyg.63:121-127.
    OpenUrlAbstract
  58. 58.↵
    Conteas, C. N., T. Sowerby, G. W. Berlin, F. Dahlan, A. Nguyen, R. Porschen, J. Donovan, M. LaRiviere, and J. M. Orenstein. 1996. Fluorescence techniques for diagnosing intestinal microsporidiosis in stool, enteric fluid, and biopsy specimens from acquired immunodeficiency syndrome patients with chronic diarrhea. Arch. Pathol. Lab. Med.120:847-853.
    OpenUrlPubMedWeb of Science
  59. 59.↵
    Costa Guimaraes, A., L. Azevedo Vinhaes, A. Santos Filho, J. Pericles Esteves, and W. Neves Abreu. 1974. Acute suppurative amebic pericarditis. Am. J. Cardiol.34:103-106.
    OpenUrlCrossRefPubMed
  60. 60.
    Cotte, L., M. Rabodonirina, M. A. Piens, M. Perreard, M. Mojon, and C. Trepo. 1993. Prevalence of intestinal protozoans in French patients infected with HIV. J. Acquir. Immune Defic. Syndr.6:1024-1029.
    OpenUrlPubMedWeb of Science
  61. 61.↵
    Crotti, D., M. L. D'Annibale, G. Fonzo, M. Lalle, S. M. Caccio, and E. Pozio. 2005. Dientamoeba fragilis is more prevalent than Giardia duodenalis in children and adults attending a day care centre in Central Italy. Parasite12:165-170.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    Cruz-Reyes, J. A., W. M. Spice, T. Rehman, E. Gisborne, and J. P. Ackers. 1992. Ribosomal DNA sequences in the differentiation of pathogenic and non-pathogenic isolates of Entamoeba histolytica. Parasitology104:239-246.
    OpenUrlCrossRefPubMed
  63. 63.↵
    Da Silva, A. J., S. B. Slemenda, G. S. Visvesvara, D. A. Schwartz, C. M. Wilcox, S. Wallace, and N. J. Pieniazek. 1997. Detection of Septata intestinalis (Microsporidia) Cali et al. 1993 Using polymerase chain reaction primers targeting the small submit subunit ribosomal RNA coding region. Mol. Diagn.2:47-52.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    Dawson, D. 2005. Foodborne protozoan parasites. Int. J. Food Microbiol.103:207-227.
    OpenUrlCrossRefPubMed
  65. 65.↵
    DeHovitz, J. A., J. W. Pape, M. Boncy, and W. D. Johnson, Jr. 1986. Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med.315:87-90.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    del Aguila, C., R. Lopez-Velez, S. Fenoy, C. Turrientes, J. Cobo, R. Navajas, G. S. Visvesvara, G. P. Croppo, A. J. Da Silva, and N. J. Pieniazek. 1997. Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis. J. Clin. Microbiol.35:1862-1866.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    Denkinger, C. M., P. Harigopal, P. Ruiz, and L. M. Dowdy. 2008. Cryptosporidium parvum-associated sclerosing cholangitis in a liver transplant patient. Transpl. Infect. Dis.10:133-136.
    OpenUrlCrossRefPubMed
  68. 68.↵
    Diamond, L. S., and C. G. Clark. 1993. A redescription of Entamoeba histolytica Schaudinn, 1903 (Emended Walker, 1911) separating it from Entamoeba dispar Brumpt, 1925. J. Eukaryot. Microbiol.40:340-344.
    OpenUrlCrossRefPubMedWeb of Science
  69. 69.↵
    Didier, E. S. 1997. Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Antimicrob. Agents Chemother.41:1541-1546.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    Didier, E. S., J. M. Orenstein, A. Aldras, D. Bertucci, L. B. Rogers, and F. A. Janney. 1995. Comparison of three staining methods for detecting microsporidia in fluids. J. Clin. Microbiol.33:3138-3145.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    Didier, E. S., L. B. Rogers, A. D. Brush, S. Wong, V. Traina-Dorge, and D. Bertucci. 1996. Diagnosis of disseminated microsporidian Encephalitozoon hellem infection by PCR-Southern analysis and successful treatment with albendazole and fumagillin. J. Clin. Microbiol.34:947-952.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    Didier, E. S., P. W. Varner, P. J. Didier, A. M. Aldras, N. J. Millichamp, M. Murphey-Corb, R. Bohm, and J. A. Shadduck. 1994. Experimental microsporidiosis in immunocompetent and immunodeficient mice and monkeys. Folia Parasitol. (Prague)41:1-11.
    OpenUrl
  73. 73.↵
    Didier, P. J., J. N. Phillips, D. J. Kuebler, M. Nasr, P. J. Brindley, M. E. Stovall, L. C. Bowers, and E. S. Didier. 2006. Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo. Antimicrob. Agents Chemother.50:2146-2155.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    Dionisio, D., L. I. Manneschi, S. Di Lollo, A. Orsi, G. Sterrantino, M. Meli, M. Gabbrielli, A. Tani, A. Papucci, and F. Leoncini. 1997. Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after furazolidone. J. Clin. Pathol.50:472-476.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    Dobell, C. 1940. Researches on the intestinal protozoa of monkeys and man. X. The life history of Dientamoeba fragilis: observations, experiments and speculations. Parasitology32:417-461.
    OpenUrlCrossRef
  76. 76.↵
    Doller, P. C., K. Dietrich, N. Filipp, S. Brockmann, C. Dreweck, R. Vonthein, C. Wagner-Wiening, and A. Wiedenmann. 2002. Cyclosporiasis outbreak in Germany associated with the consumption of salad. Emerg. Infect. Dis.8:992-994.
    OpenUrlCrossRefPubMed
  77. 77.↵
    Dowd, S. E., C. P. Gerba, F. J. Enriquez, and I. L. Pepper. 1998. PCR amplification and species determination of microsporidia in formalin-fixed feces after immunomagnetic separation. Appl. Environ. Microbiol.64:333-336.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    Dryden, M. S., and D. C. Shanson. 1988. The microbial causes of diarrhoea in patients infected with the human immunodeficiency virus. J. Infect.17:107-114.
    OpenUrlCrossRefPubMed
  79. 79.↵
    Dwivedi, K. K., G. Prasad, S. Saini, S. Mahajan, S. Lal, and U. K. Baveja. 2007. Enteric opportunistic parasites among HIV infected individuals: associated risk factors and immune status. Jpn. J. Infect. Dis.60:76-81.
    OpenUrlPubMed
  80. 80.↵
    Eckmann, L. 2003. Mucosal defences against Giardia. Parasite Immunol.25:259-270.
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    Endeshaw, T., A. Kebede, J. J. Verweij, A. Zewide, K. Tsige, Y. Abraham, D. Wolday, T. Woldemichael, T. Messele, A. M. Polderman, and B. Petros. 2006. Intestinal microsporidiosis in diarrheal patients infected with human immunodeficiency virus-1 in Addis Ababa, Ethiopia. Jpn. J. Infect. Dis.59:306-310.
    OpenUrlPubMed
  82. 82.
    Escobedo, A. A., and F. A. Nunez. 1999. Prevalence of intestinal parasites in Cuban acquired immunodeficiency syndrome (AIDS) patients. Acta Trop.72:125-130.
    OpenUrlCrossRefPubMed
  83. 83.↵
    Esfandiari, A., J. Swartz, and S. Teklehaimanot. 1997. Clustering of giardiosis among AIDS patients in Los Angeles County. Cell Mol. Biol.43:1077-1083.
    OpenUrlPubMed
  84. 84.↵
    Evangelopoulos, A., N. Legakis, and N. Vakalis. 2001. Microscopy, PCR and ELISA applied to the epidemiology of amoebiasis in Greece. Parasitol. Int.50:185-189.
    OpenUrlCrossRefPubMed
  85. 85.↵
    Farthing, M. J. G. 2006. Treatment options for the eradication of intestinal protozoa. Nat. Clin. Practice Gastroenterol. Hepatol.3:436-445.
    OpenUrlCrossRef
  86. 86.↵
    Faubert, G. 2000. Immune response to Giardia duodenalis. Clin. Microbiol. Rev.13:35-54.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    Ferreira, F. M., L. Bezerra, M. B. Santos, R. M. Bernardes, I. Avelino, and M. L. Silva. 2001. Intestinal microsporidiosis: a current infection in HIV-seropositive patients in Portugal. Microbes Infect.3:1015-1019.
    OpenUrlCrossRefPubMedWeb of Science
  88. 88.↵
    Field, A. S., M. C. Hing, S. T. Milliken, and D. J. Marriott. 1993. Microsporidia in the small intestine of HIV-infected patients. A new diagnostic technique and a new species. Med. J. Aust.158:390-394.
    OpenUrlPubMedWeb of Science
  89. 89.↵
    Field, A. S., D. J. Marriott, and M. C. Hing. 1993. The Warthin-Starry stain in the diagnosis of small intestinal microsporidiosis in HIV-infected patients. Folia Parasitol. (Prague)40:261-266.
    OpenUrl
  90. 90.↵
    Fleming, C. A., D. Caron, J. E. Gunn, and M. A. Barry. 1998. A foodborne outbreak of Cyclospora cayetanesis at a wedding: clinical features and risk factors for illness. Arch. Intern. Med.158:1121-1125.
    OpenUrlCrossRefPubMedWeb of Science
  91. 91.↵
    Fotedar, R., D. Stark, N. Beebe, D. Marriott, J. Ellis, and J. Harkness. 2007. Laboratory diagnostic techniques for Entamoeba species. Clin. Microbiol. Rev.20:511-532.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    Fotedar, R., D. Stark, N. Beebe, D. Marriott, J. Ellis, and J. Harkness. 2007. PCR detection of Entamoeba histolytica,Entamoeba dispar, and Entamoeba moshkovskii in stool samples from Sydney, Australia. J. Clin. Microbiol.45:1035-1037.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    Fotedar, R., D. Stark, D. Marriott, J. Ellis, and J. Harkness. 2008. Entamoeba moshkovskii infections in Sydney, Australia. Eur. J. Clin. Microbiol. Infect. Dis.27:133-137.
    OpenUrlCrossRefPubMedWeb of Science
  94. 94.↵
    Fournier, S., S. Dubrou, O. Liguory, F. Gaussin, M. Santillana-Hayat, C. Sarfati, J. M. Molina, and F. Derouin. 2002. Detection of microsporidia, cryptosporidia and giardia in swimming pools: a one-year prospective study. FEMS Immunol. Med. Microbiol.33:209-213.
    OpenUrlCrossRefPubMed
  95. 95.↵
    Fournier, S., O. Liguory, M. Santillana-Hayat, E. Guillot, C. Sarfati, N. Dumoutier, J. Molina, and F. Derouin. 2000. Detection of microsporidia in surface water: a one-year follow-up study. FEMS Immunol. Med. Microbiol.29:95-100.
    OpenUrlCrossRefPubMed
  96. 96.↵
    Franzen, C., A. Muller, P. Hartmann, P. Hegener, M. Schrappe, V. Diehl, G. Fatkenheuer, and B. Salzberger. 1998. Polymerase chain reaction for diagnosis and species differentiation of microsporidia. Folia Parasitol. (Prague)45:140-148.
    OpenUrl
  97. 97.↵
    Franzen, C., A. Muller, B. Salzberger, G. Fatkenheuer, S. Eidt, G. Mahrle, V. Diehl, and M. Schrappe. 1995. Tissue diagnosis of intestinal microsporidiosis using a fluorescent stain with Uvitex 2B. J. Clin. Pathol.48:1009-1010.
    OpenUrlAbstract/FREE Full Text
  98. 98.↵
    Fryauff, D. J., R. Krippner, P. Prodjodipuro, C. Ewald, S. Kawengian, K. Pegelow, T. Yun, C. von Heydwolff-Wehnert, B. Oyofo, and R. Gross. 1999. Cyclospora cayetanensis among expatriate and indigenous populations of West Java, Indonesia. Emerg. Infect. Dis.5:585-588.
    OpenUrlCrossRefPubMedWeb of Science
  99. 99.↵
    Garcia, L. S. 2001. Diagnostic medical parasitology. ASM Press,Washington, DC.
  100. 100.↵
    Garcia, L. S., and R. Y. Shimizu. 2000. Detection of Giardia lamblia and Cryptosporidium parvum antigens in human fecal specimens using the ColorPAC combination rapid solid-phase qualitative immunochromatographic assay. J. Clin. Microbiol.38:1267-1268.
    OpenUrlAbstract/FREE Full Text
  101. 101.↵
    Garcia, L. S., R. Y. Shimizu, and C. N. Bernard. 2000. Detection of Giardia lamblia,Entamoeba histolytica/Entamoebadispar, and Cryptosporidium parvum antigens in human fecal specimens using the triage parasite panel enzyme immunoassay. J. Clin. Microbiol.38:3337-3340.
    OpenUrlAbstract/FREE Full Text
  102. 102.↵
    Garcia, L. S., R. Y. Shimizu, S. Novak, M. Carroll, and F. Chan. 2003. Commercial assay for detection of Giardia lamblia and Cryptosporidium parvum antigens in human fecal specimens by rapid solid-phase qualitative immunochromatography. J. Clin. Microbiol.41:209-212.
    OpenUrlAbstract/FREE Full Text
  103. 103.↵
    Gardner, T. B., and D. R. Hill. 2001. Treatment of giardiasis. Clin. Microbiol. Rev.14:114-128.
    OpenUrlAbstract/FREE Full Text
  104. 104.↵
    Gassama, A., P. S. Sow, F. Fall, P. Camara, A. Gueye-N′diaye, R. Seng, B. Samb, S. M'Boup, and A. Aidara-Kane. 2001. Ordinary and opportunistic enteropathogens associated with diarrhea in Senegalese adults in relation to human immunodeficiency virus serostatus. Int. J. Infect. Dis.5:192-198.
    OpenUrlCrossRefPubMed
  105. 105.↵
    Gazzard, B. 2005. AIDS and the gastrointestinal tract. Medicine33:24-26.
    OpenUrl
  106. 106.↵
    Ghosh, S., A. Debnath, A. Sil, S. De, D. J. Chattopadhyay, and P. Das. 2000. PCR detection of Giardia lamblia in stool: targeting intergenic spacer region of multicopy rRNA gene. Mol. Cell Probes14:181-189.
    OpenUrlCrossRefPubMedWeb of Science
  107. 107.↵
    Gile, M., D. C. Warhurst, K. A. Webster, D. M. West, and J. A. Marshall. 2002. A multiplex allele specific polymerase chain reaction (MAS-PCR) on the dihydrofolate reductase gene for the detection of Cryptosporidium parvum genotypes 1 and 2. Parasitology125:35-44.
    OpenUrlPubMed
  108. 108.↵
    Girginkardesler, N., S. Coskun, I. Cuneyt Balcioglu, P. Ertan, and U. Z. Ok. 2003. Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole. Clin. Microbiol. Infect.9:110-113.
    OpenUrlCrossRefPubMedWeb of Science
  109. 109.↵
    Gliullo, A. B. D., M. S. Cribari, A. J. Bava, J. S. Cicconetti, and R. Collazos. 2000. Cyclospora cayetanensis in sputum and stool samples. Rev. Inst. Med. Trop. Sao Paulo42:115-117.
    OpenUrlPubMed
  110. 110.↵
    Goetz, M., S. Eichenlaub, G. R. Pape, and R. M. Hoffmann. 2001. Chronic diarrhea as a result of intestinal microsposidiosis in a liver transplant recipient. Transplantation71:334-337.
    OpenUrlCrossRefPubMed
  111. 111.↵
    Gomersall, L. N., J. Currie, and R. Jeffrey. 1994. Amoebiasis: a rare cause of cardiac tamponade. Br. Heart J.71:368-369.
    OpenUrlAbstract/FREE Full Text
  112. 112.↵
    Gorgolas, M. D., J. Fortes, and M. L. F. Guerrero. 2001. Cyclospora cayetanensis cholecystitis in a patient with AIDS Ann. Intern. Med.134:166.
    OpenUrl
  113. 113.↵
    Graczyk, T. K., M. R. Cranfield, and R. Fayer. 1996. Evaluation of commercial enzyme immunoassay (EIA) and immunofluorescent antibody (FA) test kits for detection of Cryptosporidium oocysts of species other than Cryptosporidium parvum. Am. J. Trop. Med. Hyg.54:274-279.
    OpenUrlAbstract/FREE Full Text
  114. 114.↵
    Graczyk, T. K., D. Sunderland, L. Tamang, F. E. Lucy, and P. N. Breysse. 2007. Bather density and levels of Cryptosporidium, Giardia, and pathogenic microsporidian spores in recreational bathing water. Parasitol. Res.101:1729-1731.
    OpenUrlCrossRefPubMed
  115. 115.↵
    Greenberg, S. J., M. P. Davey, W. S. Zierdt, and T. A. Waldmann. 1988. Isospora belli enteric infection in patients with human T-cell leukemia virus type I-associated adult T-cell leukemia. Am. J. Med.85:435-438.
    OpenUrlCrossRefPubMed
  116. 116.↵
    Guerard, A., M. Rabodonirina, L. Cotte, O. Liguory, M. A. Piens, S. Daoud, S. Picot, and J. L. Touraine. 1999. Intestinal microsporidiosis occurring in two renal transplant recipients treated with mycophenolate mofetil. Transplantation68:699-707.
    OpenUrlCrossRefPubMed
  117. 117.↵
    Guiguet, M., A. Furco, P. Tattevin, D. Costagliola, and J. M. Molina. 2007. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV. HIV Med.8:124-130.
    OpenUrlCrossRefPubMed
  118. 118.
    Guk, S.-M., M. Seo, Y.-K. Park, M.-D. Oh, K.-W. Choe, J.-L. Kim, M.-H. Choi, S.-T. Hong, and J.-Y. Chai. 2005. Parasitic infections in HIV-infected patients who visited Seoul National University Hospital during the period 1995-2003. Korean J. Parasitol.43:1-5.
    OpenUrlPubMed
  119. 119.↵
    Gupta, Y. K., M. Gupta, S. Aneja, and K. Kohli. 2004. Current drug therapy of protozoal diarrhoea. Indian J. Pediatr.71:55-58.
    OpenUrlCrossRefPubMed
  120. 120.↵
    Guy, R. A., C. Xiao, and P. A. Horgen. 2004. Real-time PCR assay for detection and genotype differentiation of Giardia lamblia in stool specimens. J. Clin. Microbiol.42:3317-3320.
    OpenUrlAbstract/FREE Full Text
  121. 121.↵
    Guyot, K., A. Follet-Dumoulin, E. Lelievre, C. Sarfati, M. Rabodonirina, G. Nevez, J. C. Cailliez, D. Camus, and E. Dei-Cas. 2001. Molecular characterization of Cryptosporidium isolates obtained from humans in France. J. Clin. Microbiol.39:3472-3480.
    OpenUrlAbstract/FREE Full Text
  122. 122.↵
    Hailemariam, G., A. Kassu, G. Abebe, E. Abate, D. Damte, E. Mekonnen, and F. Ota. 2004. Intestinal parasitic infections in HIV/AIDS and HIV seronegative individuals in a teaching hospital, Ethiopia. Jpn. J. Infect. Dis.57:41-43.
    OpenUrlPubMed
  123. 123.↵
    Hamnes, I. S., B. Gjerde, and L. Robertson. 2006. Prevalence of Giardia and Cryptosporidium in dairy calves in three areas of Norway. Vet. Parasitol.140:204-216.
    OpenUrlCrossRefPubMedWeb of Science
  124. 124.
    Hamnes, I. S., B. Gjerde, L. Robertson, T. Vikoren, and K. Handeland. 2006. Prevalence of Cryptosporidium and Giardia in free-ranging wild cervids in Norway. Vet. Parasitol.141:30-41.
    OpenUrlCrossRefPubMed
  125. 125.
    Hamnes, I. S., B. K. Gjerde, T. Forberg, and L. J. Robertson. 2007. Occurrence of Cryptosporidium and Giardia in suckling piglets in Norway. Vet. Parasitol.144:222-233.
    OpenUrlCrossRefPubMedWeb of Science
  126. 126.↵
    Hamnes, I. S., B. K. Gjerde, T. Forberg, and L. J. Robertson. 2007. Occurrence of Giardia and Cryptosporidium in Norwegian red foxes (Vulpes vulpes). Vet. Parasitol.143:347-353.
    OpenUrlCrossRefPubMed
  127. 127.↵
    Hamzah, Z., S. Petmitr, M. Mungthin, S. Leelayoova, and P. Chavalitshewinkoon-Petmitr. 2006. Differential detection of Entamoeba histolytica,Entamoeba dispar, and Entamoeba moshkovskii by a single-round PCR assay. J. Clin. Microbiol.44:3196-3200.
    OpenUrlAbstract/FREE Full Text
  128. 128.↵
    Haque, R., N. U. Mollah, I. K. Ali, K. Alam, A. Eubanks, D. Lyerly, and W. A. Petri, Jr. 2000. Diagnosis of amebic liver abscess and intestinal infection with the TechLab Entamoeba histolytica II antigen detection and antibody tests. J. Clin. Microbiol.38:3235-3239.
    OpenUrlAbstract/FREE Full Text
  129. 129.↵
    Haque, R., L. M. Neville, P. Hahn, and W. A. Petri, Jr. 1995. Rapid diagnosis of Entamoeba infection by using Entamoeba and Entamoeba histolytica stool antigen detection kits. J. Clin. Microbiol.33:2558-2561.
    OpenUrlAbstract/FREE Full Text
  130. 130.↵
    Hart, C. A., N. J. Beeching, B. I. Duerden, A. Curry, N. French, S. Kariuki, S. M. Graham, M. A. Gordon, P. G. Hoggard, S. Kewn, and D. J. Back. 2000. Infections in AIDS. J. Med. Microbiol.49:947-967.
    OpenUrlPubMedWeb of Science
  131. 131.↵
    Hartskeerl, R. A., A. R. Schuitema, T. van Gool, and W. J. Terpstra. 1993. Genetic evidence for the occurrence of extra-intestinal Enterocytozoon bieneusi infections. Nucleic Acids Res.21:4150.
    OpenUrlCrossRefPubMed
  132. 132.↵
    Hegner, R., and H. J. Chu. 1930. A comparative study of the intestinal protozoa of wild monkeys and man. Am. J. Hyg.12:62-108.
    OpenUrl
  133. 133.↵
    Helmy, M. M., L. A. Rashed, and H. S. Abdel-Fattah. 2006. Co-infection with Cryptosporidium parvum and Cyclospora cayetanensis in immunocompromised patients. J. Egypt. Soc. Parasitol.36:613-627.
    OpenUrlPubMed
  134. 134.↵
    Heresi, G. P., J. R. Murphy, and T. G. Cleary. 2000. Giardiasis. Semin. Pediatr. Infect. Dis.11:189-195.
    OpenUrlCrossRef
  135. 135.↵
    Hibbett, D. S., M. Binder, J. F. Bischoff, M. Blackwell, P. F. Cannon, O. E. Eriksson, S. Huhndorf, T. James, P. M. Kirk, R. Lucking, H. Thorsten Lumbsch, F. Lutzoni, P. B. Matheny, D. J. McLaughlin, M. J. Powell, S. Redhead, C. L. Schoch, J. W. Spatafora, J. A. Stalpers, R. Vilgalys, M. C. Aime, A. Aptroot, R. Bauer, D. Begerow, G. L. Benny, L. A. Castlebury, P. W. Crous, Y. C. Dai, W. Gams, D. M. Geiser, G. W. Griffith, C. Gueidan, D. L. Hawksworth, G. Hestmark, K. Hosaka, R. A. Humber, K. D. Hyde, J. E. Ironside, U. Koljalg, C. P. Kurtzman, K. H. Larsson, R. Lichtwardt, J. Longcore, J. Miadlikowska, A. Miller, J. M. Moncalvo, S. Mozley-Standridge, F. Oberwinkler, E. Parmasto, V. Reeb, J. D. Rogers, C. Roux, L. Ryvarden, J. P. Sampaio, A. Schussler, J. Sugiyama, R. G. Thorn, L. Tibell, W. A. Untereiner, C. Walker, Z. Wang, A. Weir, M. Weiss, M. M. White, K. Winka, Y. J. Yao, and N. Zhang. 2007. A higher-level phylogenetic classification of the fungi. Mycol. Res.111:509-547.
    OpenUrlCrossRefPubMedWeb of Science
  136. 136.↵
    Higgins, J. A., R. Fayer, J. M. Trout, L. Xiao, A. A. Lal, S. Kerby, and M. C. Jenkins. 2001. Real-time PCR for the detection of Cryptosporidium parvum. J. Microbiol. Methods47:323-337.
    OpenUrlCrossRefPubMedWeb of Science
  137. 137.↵
    Ho, A. Y., A. S. Lopez, M. G. Eberhart, R. Levenson, B. S. Finkel, A. J. da Silva, J. M. Roberts, P. A. Orlandi, C. C. Johnson, and B. L. Herwaldt. 2002. Outbreak of cyclosporiasis associated with imported raspberries, Philadelphia, Pennsylvania, 2000. Emerg. Infect. Dis.8:783-788.
    OpenUrlCrossRefPubMedWeb of Science
  138. 138.↵
    Hoang, L. M., M. Fyfe, C. Ong, J. Harb, S. Champagne, B. Dixon, and J. Isaac-Renton. 2005. Outbreak of cyclosporiasis in British Columbia associated with imported Thai basil. Epidemiol. Infect.133:23-27.
    OpenUrlCrossRefPubMed
  139. 139.↵
    Hodge, C. W., D. R. Shilm, M. Ghimire, J. G. Rabold, P. Pandey, A. Walch, R. Rajah, P. Gaudio, and P. Echeverria. 1995. Placebo-controlled trial of cotrimoxazole for Cyclospora infections among travellers and foreign residents in Nepal. Lancet345:691-693.
    OpenUrlCrossRefPubMedWeb of Science
  140. 140.↵
    Hong, D. K., C. J. Wong, and K. Gutierrez. 2007. Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature. Pediatr. Transplant.11:94-100.
    OpenUrlCrossRefPubMed
  141. 141.↵
    Hoza, J. 1966. Secondary reactions of some new antibiotics. Fumagillin. Lek Veda Zahr8:156-157.
    OpenUrl
  142. 142.↵
    Hsieh, S. M., M. Y. Chen, S. C. Pan, C. C. Hung, and S. C. Chang. 2007. Aberrant induction of regulatory activity of CD4+CD25+ T cells by dendritic cells in HIV-infected persons with amebic liver abscess. J. Acquir. Immune Defic. Syndr.44:6-13.
    OpenUrlCrossRefPubMed
  143. 143.↵
    Hughes, F. B., S. T. Faehnle, and J. L. Simon. 1975. Multiple cerebral abscesses complicating hepatopulmonary amebiasis. J. Pediatr.86:95-96.
    OpenUrlCrossRefPubMedWeb of Science
  144. 144.↵
    Hung, C. C., P. J. Chen, S. M. Hsieh, J. M. Wong, C. T. Fang, S. C. Chang, and M. Y. Chen. 1999. Invasive amoebiasis: an emerging parasitic disease in patients infected with HIV in an area endemic for amoebic infection. AIDS13:2421-2428.
    OpenUrlCrossRefPubMedWeb of Science
  145. 145.
    Hung, C. C., H. Y. Deng, W. H. Hsiao, S. M. Hsieh, C. F. Hsiao, M. Y. Chen, S. C. Chang, and K. E. Su. 2005. Invasive amebiasis as an emerging parasitic disease in patients with human immunodeficiency virus type 1 infection in Taiwan. Arch. Intern. Med.165:409-415.
    OpenUrlCrossRefPubMedWeb of Science
  146. 146.↵
    Hung, C. C., D. D. Ji, H. Y. Sun, Y. T. Lee, S. Y. Hsu, S. Y. Chang, C. H. Wu, Y. H. Chan, C. F. Hsiao, W. C. Liu, and R. Colebunders. 2008. Increased risk for Entamoeba histolytica infection and invasive amebiasis in HIV seropositive men who have sex with men in Taiwan. PLoS Negl. Trop. Dis.2:e175.
    OpenUrlCrossRefPubMed
  147. 147.↵
    Jayalakshmi, J., B. Appalaraju, and K. Mahadevan. 2008. Evaluation of an enzyme-linked immunoassay for the detection of Cryptosporidium antigen in fecal specimens of HIV/AIDS patients. Indian J. Pathol. Microbiol.51:137-138.
    OpenUrlCrossRefPubMed
  148. 148.↵
    Jayshree, R. S., R. S. Acharya, and H. Sridhar. 1996. Isospora belli infection in a patient with acute lymphoblastic leukaemia in India. J. Diarrhoeal Dis. Res.14:44-45.
    OpenUrlPubMed
  149. 149.↵
    Joachim, A. 2004. Human cryptosporidiosis: an update with special emphasis on the situation in Europe. J. Vet. Med. B51:251-259.
    OpenUrlCrossRef
  150. 150.↵
    Johnson, E. H., J. J. Windsor, and C. G. Clark. 2004. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin. Microbiol. Rev.17:553-570.
    OpenUrlAbstract/FREE Full Text
  151. 151.↵
    Johnston, S. P., M. M. Ballard, M. J. Beach, L. Causer, and P. P. Wilkins. 2003. Evaluation of three commercial assays for detection of Giardia and Cryptosporidium organisms in fecal specimens. J. Clin. Microbiol.41:623-626.
    OpenUrlAbstract/FREE Full Text
  152. 152.↵
    Jongwutiwes, S., P. Sampatanukul, and C. Putaporntip. 2002. Recurrent isosporiasis over a decade in an immunocompetent host successfully treated with pyrimethamine. Scand. J. Infect. Dis.34:859-862.
    OpenUrlCrossRefPubMedWeb of Science
  153. 153.↵
    Joseph, J., G. K. Vemuganti, and S. Sharma. 2005. Microsporidia: emerging ocular pathogens. Indian J. Med. Microbiol.23:80-91.
    OpenUrlPubMed
  154. 154.↵
    Joshi, M., A. S. Chowdhary, P. J. Dalal, and J. K. Maniar. 2002. Parasitic diarrhoea in patients with AIDS. Natl. Med. J. India15:72-74.
    OpenUrlPubMed
  155. 155.↵
    Jothikumar, N., A. J. da Silva, I. Moura, Y. Qvarnstrom, and V. R. Hill. 2008. Detection and differentiation of Cryptosporidium hominis and Cryptosporidium parvum by dual TaqMan assays. J. Med. Microbiol.57:1099-1105.
    OpenUrlCrossRefPubMed
  156. 156.↵
    Karanis, P., C. Kourenti, and H. Smith. 2007. Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt. J. Water Health5:1-38.
    OpenUrlAbstract/FREE Full Text
  157. 157.↵
    Katiyar, S. K., V. R. Gordon, G. L. McLaughlin, and T. D. Edlind. 1994. Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence. Antimicrob. Agents Chemother.38:2086-2090.
    OpenUrlAbstract/FREE Full Text
  158. 158.↵
    Kaushik, K., S. Khurana, A. Wanchu, and N. Malla. 2008. Evaluation of staining techniques, antigen detection and nested PCR for the diagnosis of cryptosporidiosis in HIV seropositive and seronegative patients. Acta Trop.107:1-7.
    OpenUrlCrossRefPubMed
  159. 159.↵
    Kawano, F., K. Nishida, H. Kurisaki, A. Tsukamoto, M. Satoh, I. Sanada, T. Shido, S. Obata, K. Kimura, Y. Sasaki, et al. 1992. Isospora belli infection in a patient with adult T-cell leukemia. Rinsho Ketsueki33:683-687.
    OpenUrlPubMed
  160. 160.↵
    Kawashima, I., H. Fusegawa, M. Obana, and Y. Matsuoka. 2000. A case of AIDS complicated with liver tuberculosis. Kansenshogaku Zasshi74:984-988.
    OpenUrlPubMed
  161. 161.↵
    Kean, B. H., and C. L. Malloch. 1966. The neglected ameba: Dientamoeba fragilis. A report of 100 “pure” infections. Am. J. Dig. Dis.11:735-746.
    OpenUrlCrossRefPubMedWeb of Science
  162. 162.↵
    Kelly, P., F. Lungu, E. Keane, R. Baggaley, F. Kazembe, J. Pobee, and M. Farthing. 1996. Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. BMJ312:1187-1191.
    OpenUrlAbstract/FREE Full Text
  163. 163.↵
    Kemper, C. A. 1997. Pulmonary disease in selected protozoal infections. Semin. Respir. Infect.12:113-121.
    OpenUrlPubMed
  164. 164.↵
    Kester, K. E., G. W. Turiansky, and P. L. McEvoy. 1998. Nodular cutaneous microsporidiosis in a patient with AIDS and successful treatment with long-term oral clindamycin therapy. Ann. Intern. Med.128:911-914.
    OpenUrlPubMedWeb of Science
  165. 165.↵
    Knappik, M., U. Borner, and T. Jelinek. 2005. Sensitivity and specificity of a new commercial enzyme-linked immunoassay kit for detecting Entamoeba histolytica IgG antibodies in serum samples. Eur. J. Clin. Microbiol. Infect. Dis.24:701-703.
    OpenUrlCrossRefPubMed
  166. 166.↵
    Knoll, E. H., and K. M. Howell. 1945. Studies on Dientamoeba fragilis: its incidence and possible pathogenicity. Am. J. Clin. Pathol.15:178-183.
    OpenUrlWeb of Science
  167. 167.↵
    Knowles, R., and B. M. D. Gupta. 1936. Some observations on the intestinal protozoa of Macaques. Indian J. Med. Res.24:547-556.
    OpenUrl
  168. 168.↵
    Kochhar, A., S. Saxena, V. L. Malhotra, and M. Deb. 2007. Isospora belli infection in a malnourished child. J. Commun. Dis.39:141-143.
    OpenUrlPubMed
  169. 169.↵
    Koru, O., R. E. Araz, Y. A. Yilmaz, S. Erguven, M. Yenicesu, B. Pektas, and M. Tanyuksel. 2007. Isospora belli infection in a renal transplant recipent. Turkiye Parazitol. Derg.31:98-100.
    OpenUrlPubMed
  170. 170.↵
    Kosek, M., C. Bern, and R. L. Guerrant. 2003. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull. W. H. O.81:197-204.
    OpenUrlCrossRefPubMedWeb of Science
  171. 171.↵
    Lalonde, L. F., and A. A. Gajadhar. 2008. Highly sensitive and specific PCR assay for reliable detection of Cyclospora cayetanensis oocysts. Appl. Environ. Microbiol.74:4354-4358.
    OpenUrlAbstract/FREE Full Text
  172. 172.↵
    Lasser, K. H., K. J. Lewin, and F. W. Ryning. 1979. Cryptosporidial enteritis in a patient with congenital hypogammaglobulinemia. Hum. Pathol.10:234-240.
    OpenUrlCrossRefPubMedWeb of Science
  173. 173.↵
    Law, C. L., J. Walker, and M. H. Qassim. 1991. Factors associated with the detection of Entamoeba histolytica in homosexual men. Int. J. STD AIDS2:346-350.
    OpenUrlPubMedWeb of Science
  174. 174.
    Lebbad, M., H. Norrgren, A. Naucler, F. Dias, S. Andersson, and E. Linder. 2001. Intestinal parasites in HIV-2 associated AIDS cases with chronic diarrhoea in Guinea-Bissau. Acta Trop.80:45-49.
    OpenUrlCrossRefPubMedWeb of Science
  175. 175.↵
    Leder, K., M. E. Hellard, M. I. Sinclair, C. K. Fairley, and R. Wolfe. 2005. No correlation between clinical symptoms and Blastocystis hominis in immunocompetent individuals. J. Gastroenterol. Hepatol.20:1390-1394.
    OpenUrlCrossRefPubMed
  176. 176.↵
    Leelayoova, S., R. Rangsin, P. Taamasri, T. Naaglor, U. Thathaisong, and M. Mungthin. 2004. Evidence of waterborne transmission of Blastocystis hominis. Am. J. Trop. Med. Hyg.70:658-662.
    OpenUrlAbstract/FREE Full Text
  177. 177.↵
    Levy, Y., J. George, and Y. Shoenfeld. 1996. Severe Blastocystis hominis in an elderly man. J. Infect.33:57-59.
    OpenUrlCrossRefPubMed
  178. 178.↵
    Lewthwaite, P., G. V. Gill, C. A. Hart, and N. J. Beeching. 2005. Gastrointestinal parasites in the immunocompromised. Curr. Opin. Infect. Dis.18:427-435.
    OpenUrlCrossRefPubMedWeb of Science
  179. 179.
    Lindo, J. F., J. M. Dubon, A. L. Ager, E. M. De Gourville, H. Solo-Gabriele, W. I. Klaskala, M. K. Baum, and C. J. Palmer. 1998. Intestinal parasitic infections in human immunodeficiency virus (HIV)-positive and HIV-negative individuals in San Pedro Sula, Honduras. Am. J. Trop. Med. Hyg.58:431-435.
    OpenUrlAbstract
  180. 180.↵
    Lopez, A. D., C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. Murray. 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet367:1747-1757.
    OpenUrlCrossRefPubMedWeb of Science
  181. 181.↵
    Lopez, A. S., D. R. Dodson, M. J. Arrowood, P. A. Orlandi Jr., A. J. da Silva, J. W. Bier, S. D. Hanauer, R. L. Kuster, S. Oltman, M. S. Baldwin, K. Y. Won, E. M. Nace, M. L. Eberhard, and B. L. Herwaldt. 2001. Outbreak of cyclosporiasis associated with basil in Missouri in 1999. Clin. Infect. Dis.32:1010-1017.
    OpenUrlCrossRefPubMed
  182. 182.↵
    Lowther, S. A., M. S. Dworkin, and D. L. Hanson. 2000. Entamoeba histolytica/Entamoeba dispar infections in human immunodeficiency virus-infected patients in the United States. Clin. Infect. Dis.30:955-959.
    OpenUrlCrossRefPubMedWeb of Science
  183. 183.↵
    Majmudar, B., M. L. Chaiken, and K. U. Lee. 1976. Amebiasis of clitoris mimicking carcinoma. JAMA236:1145-1146.
    OpenUrlCrossRefPubMedWeb of Science
  184. 184.↵
    Martino, P., G. Gentile, A. Caprioli, L. Baldassarri, G. Donelli, W. Arcese, S. Fenu, A. Micozzi, M. Venditti, and F. Mandelli. 1988. Hospital-acquired cryptosporidiosis in a bone marrow transplantation unit. J. Infect. Dis.158:647-648.
    OpenUrlCrossRefPubMed
  185. 185.↵
    Mathers, C. D., and D. Loncar. 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med.3:e442.
    OpenUrlCrossRefPubMed
  186. 186.↵
    Matsukawa, A. 2007. STAT proteins in innate immunity during sepsis: lessons from gene knockout mice. Acta Med. Okayama61:239-245.
    OpenUrlPubMed
  187. 187.↵
    McDonald, V. 2000. Host cell-mediated responses to infection with Cryptosporidium. Parasite Immunol.22:597-604.
    OpenUrlCrossRefPubMedWeb of Science
  188. 188.↵
    McDonald, V., R. Smith, H. Robinson, and G. Bancroft. 2000. Host immune responses against Cryptosporidium. Contrib. Microbiol.6:75-91.
    OpenUrlCrossRefPubMed
  189. 189.↵
    Mendez, O. C., G. Szmulewicz, C. Menghi, S. Torres, G. Gonzalez, and C. Gatta. 1994. Comparison of intestinal parasite infestation indexes among HIV positive and negative populations. Medicina (Buenos Aires)54:307-310.
    OpenUrl
  190. 190.↵
    Metge, S., J. T. Van Nhieu, D. Dahmane, P. Grimbert, F. Foulet, C. Sarfati, and S. Bretagne. 2000. A case of Enterocytozoon bieneusi infection in an HIV-negative renal transplant recipient. Eur. J. Clin. Microbiol. Infect. Dis.19:221-223.
    OpenUrlCrossRefPubMed
  191. 191.↵
    Miao, Y. M., F. M. Awad-El-Kariem, C. Franzen, D. S. Ellis, A. Muller, H. M. Counihan, P. J. Hayes, and B. G. Gazzard. 2000. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndr.25:124-129.
    OpenUrlCrossRefPubMedWeb of Science
  192. 192.
    Mohandas, K., R. Sehgal, A. Sud, and N. Malla. 2002. Prevalence of intestinal parasitic pathogens in HIV-seropositive individuals in Northern India. Jpn. J. Infect. Dis.55:83-84.
    OpenUrlPubMed
  193. 193.↵
    Molina, J. M., C. Chastang, J. Goguel, J. F. Michiels, C. Sarfati, I. Desportes-Livage, J. Horton, F. Derouin, and J. Modai. 1998. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J. Infect. Dis.177:1373-1377.
    OpenUrlCrossRefPubMedWeb of Science
  194. 194.↵
    Molina, J. M., J. Goguel, C. Sarfati, C. Chastang, I. Desportes-Livage, J. F. Michiels, C. Maslo, C. Katlama, L. Cotte, C. Leport, F. Raffi, F. Derouin, J. Modai, et al. 1997. Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study. AIDS11:1603-1610.
    OpenUrlCrossRefPubMedWeb of Science
  195. 195.↵
    Molina, J. M., M. Tourneur, C. Sarfati, S. Chevret, A. de Gouvello, J. G. Gobert, S. Balkan, and F. Derouin. 2002. Fumagillin treatment of intestinal microsporidiosis. N. Engl. J. Med.346:1963-1969.
    OpenUrlCrossRefPubMedWeb of Science
  196. 196.↵
    Moolasart, P. 1999. Giardia lamblia in AIDS patients with diarrhea. J. Med. Assoc. Thailand82:654-659.
    OpenUrlPubMed
  197. 197.↵
    Morales Gomez, M. A. 2004. Highly active antiretroviral therapy and cryptosporidiosis. Parassitologia46:95-99.
    OpenUrlPubMed
  198. 198.↵
    Morgan, U., R. Weber, L. Xiao, I. Sulaiman, R. C. Thompson, W. Ndiritu, A. Lal, A. Moore, and P. Deplazes. 2000. Molecular characterization of Cryptosporidium isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya, and the United States. J. Clin. Microbiol.38:1180-1183.
    OpenUrlAbstract/FREE Full Text
  199. 199.↵
    Morgan, U. M., L. Pallant, B. W. Dwyer, D. A. Forbes, G. Rich, and R. C. Thompson. 1998. Comparison of PCR and microscopy for detection of Cryptosporidium parvum in human fecal specimens: clinical trial. J. Clin. Microbiol.36:995-998.
    OpenUrlAbstract/FREE Full Text
  200. 200.↵
    Moura, H., F. C. Sodre, F. J. Bornay-Llinares, G. J. Leitch, T. Navin, S. Wahlquist, R. Bryan, I. Meseguer, and G. S. Visvesvara. 1999. Detection by an immunofluorescence test of Encephalitozoon intestinalis spores in routinely formalin-fixed stool samples stored at room temperature. J. Clin. Microbiol.37:2317-2322.
    OpenUrlAbstract/FREE Full Text
  201. 201.↵
    Mukhopadhyay, C., G. Wilson, D. Pradhan, and P. G. Shivananda. 2007. Intestinal protozoal infestation profile in persistent diarrhea in children below age 5 years in western Nepal. Southeast Asian J. Trop. Med. Public Health38:13-19.
    OpenUrlPubMed
  202. 202.↵
    Muller, A., R. Bialek, G. Fatkenheuer, B. Salzberger, V. Diehl, and C. Franzen. 2000. Detection of Isospora belli by polymerase chain reaction using primers based on small-subunit ribosomal RNA sequences. Eur. J. Clin. Microbiol. Infect. Dis.19:631-634.
    OpenUrlCrossRefPubMed
  203. 203.↵
    Mwachari, C., B. I. F. Batchelor, J. Paul, P. G. Waiyaki, and C. F. Gilks. 1998. Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya. J. Infect.37:48-53.
    OpenUrlCrossRefPubMedWeb of Science
  204. 204.↵
    Myers, B. J., and R. E. Kuntz. 1968. Intestinal protozoa of the baboon Papio doguera Pucheran, 1856. J. Protozool.15:363-365.
    OpenUrlCrossRefPubMed
  205. 205.↵
    Nahrevanian, H., and M. Assmar. 2008. Cryptosporidiosis in immunocompromised patients in the Islamic Republic of Iran. J. Microbiol. Immunol. Infect.41:74-77.
    OpenUrlPubMed
  206. 206.↵
    Navaneethan, U., and R. A. Giannella. 2008. Mechanisms of infectious diarrhea. Nat. Clin. Pract. Gastroenterol. Hepatol.5:637-647.
    OpenUrlCrossRefPubMed
  207. 207.↵
    Navin, T. R., R. Weber, D. J. Vugia, D. Rimland, J. M. Roberts, D. G. Addiss, G. S. Visvesvara, S. P. Wahlquist, S. E. Hogan, L. E. Gallagher, D. D. Juranek, D. A. Schwartz, C. M. Wilcox, J. M. Stewart, S. E. Thompson III, and R. T. Bryan. 1999. Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: results of a 3-year longitudinal study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.20:154-159.
    OpenUrlCrossRefPubMed
  208. 208.↵
    Ng, J., I. Pavlasek, and U. Ryan. 2006. Identification of novel Cryptosporidium genotypes from avian hosts. Appl. Environ. Microbiol.72:7548-7553.
    OpenUrlAbstract/FREE Full Text
  209. 209.↵
    Nkinin, S. W., T. Asonganyi, E. S. Didier, and E. S. Kaneshiro. 2007. Microsporidian infection is prevalent in healthy people in Cameroon. J. Clin. Microbiol.45:2841-2846.
    OpenUrlAbstract/FREE Full Text
  210. 210.↵
    Norhayati, M., M. Azlin, M. H. Al-Mekhlafi, N. Anisah, U. Nor Aini, M. S. Fatmah, and A. R. Rozlida. 2008. A preliminary study on the prevalence of intestinal microsporidiosis in patients with and without gastrointestinal symptoms in Malaysia. Trans. R. Soc. Trop. Med. Hyg.102:1274-1278.
    OpenUrlCrossRefPubMed
  211. 211.↵
    Noureldin, M. S., A. A. Shaltout, E. M. El Hamshary, and M. E. Ali. 1999. Opportunistic intestinal protozoal infections in immunocompromised children. J. Egypt. Soc. Parasitol.29:951-961.
    OpenUrlPubMed
  212. 212.↵
    O'Donoghue, P. J. 1985. Cryptosporidium infections in man, animals, birds and fish. Aust. Vet. J.62:253-258.
    OpenUrlCrossRefPubMed
  213. 213.↵
    Ohnishi, K., M. Murata, and E. Okuzawa. 1994. Symptomatic amebic colitis in a Japanese homosexual AIDS patient. Intern. Med.33:120-122.
    OpenUrlPubMedWeb of Science
  214. 214.↵
    Ohtaki, M., Y. Michimata, T. Suzuki, K. Oikawa, and M. Mikami. 1976. Malignant lymphoma initiated with malabsorption syndrome due to Isospora belli infection and lymphocytosis. Tohoku J. Exp. Med.120:43-51.
    OpenUrlPubMed
  215. 215.↵
    Osman, G. A., K. M. Makled, H. M. El-Shakankiry, D. M. Metwali, S. S. Abdel-Aziz, and H. H. Saafan. 1999. Coccidian parasites as a cause of watery diarrhoea among protein energy malnourished and other immunocompromised Egyptian children. J. Egypt. Soc. Parasitol.29:653-668.
    OpenUrlPubMed
  216. 216.↵
    Oster, N., H. Gehrig-Feistel, H. Jung, J. Kammer, J. E. McLean, and M. Lanzer. 2006. Evaluation of the immunochromatographic CORIS Giardia-Strip test for rapid diagnosis of Giardia lamblia. Eur. J. Clin. Microbiol. Infect. Dis.25:112-115.
    OpenUrlCrossRefPubMed
  217. 217.↵
    Othman, N. H., and A. N. Ismail. 1993. Endometrial amoebiasis. Eur. J. Obstet. Gynecol. Reprod. Biol.52:135-137.
    OpenUrlCrossRefPubMedWeb of Science
  218. 218.↵
    Palmieri, F., S. Cicalini, N. Froio, E. B. Rizzi, D. Goletti, A. Festa, G. Macri, and N. Petrosillo. 2005. Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. Int. J. STD AIDS16:515-517.
    OpenUrlCrossRefPubMedWeb of Science
  219. 219.↵
    Pape, J. W., R. I. Verdier, and W. D. Johnson, Jr. 1989. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med.320:1044-1047.
    OpenUrlCrossRefPubMedWeb of Science
  220. 220.↵
    Parija, S. C., and K. Khairnar. 2007. Detection of excretory Entamoeba histolytica DNA in the urine, and detection of E. histolytica DNA and lectin antigen in the liver abscess pus for the diagnosis of amoebic liver abscess. BMC Microbiol.7:41.
    OpenUrlCrossRefPubMed
  221. 221.↵
    Parija, S. C., and K. Khairnar. 2005. Entamoeba moshkovskii and Entamoeba dispar-associated infections in pondicherry, India. J. Health Popul. Nutr.23:292-295.
    OpenUrlPubMedWeb of Science
  222. 222.↵
    Parkar, U., R. J. Traub, S. Kumar, M. Mungthin, S. Vitali, S. Leelayoova, K. Morris, and R. C. Thompson. 2007. Direct characterization of Blastocystis from faeces by PCR and evidence of zoonotic potential. Parasitology134:359-367.
    OpenUrlCrossRefPubMedWeb of Science
  223. 223.↵
    Paziewska, A., M. Bednarska, H. Nieweglowski, G. Karbowiak, and A. Bajer. 2007. Distribution of Cryptosporidium and Giardia spp. in selected species of protected and game mammals from north-eastern Poland. Ann. Agric. Environ. Med.14:265-270.
    OpenUrlPubMed
  224. 224.↵
    Pedraza-Diaz, S., C. F. L. Amar, J. McLauchlin, G. L. Nichols, K. M. Cotton, P. Godwin, A. M. Iversen, L. Milne, J. R. Mulla, K. Nye, H. Panigrahl, S. R. Venn, R. Wiggins, M. Williams, and E. R. Youngs. 2001. Cryptosporidium meleagridis from humans: molecular analysis and description of affected patients. J. Infect.42:243-250.
    OpenUrlCrossRefPubMedWeb of Science
  225. 225.↵
    Peng, C. Y., and W. Tsai. 1991. Isospora belli infection in a patient with Hodgkin's disease: report of a case. J. Formos. Med. Assoc.90:260-263.
    OpenUrlPubMed
  226. 226.↵
    Pol, S., C. A. Romana, S. Richard, P. Amouyal, I. Desportes-Livage, F. Carnot, J. F. Pays, and P. Berthelot. 1993. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N. Engl. J. Med.328:95-99.
    OpenUrlCrossRefPubMedWeb of Science
  227. 227.↵
    Pollok, R. C., and M. J. Farthing. 2000. Enteric viruses in HIV-related diarrhoea. Mol. Med. Today6:483-487.
    OpenUrlCrossRefPubMed
  228. 228.↵
    Pozio, E. 2004. Highly active antiretroviral therapy and opportunistic protozoan infections. Parassitologia46:89-93.
    OpenUrlPubMed
  229. 229.
    Prasad, K. N., V. L. Nag, T. N. Dhole, and A. Ayyagari. 2000. Identification of enteric pathogens in HIV-positive patients with diarrhoea in northern India. J. Health Popul. Nutr.18:23-26.
    OpenUrlPubMedWeb of Science
  230. 230.↵
    Preiss, U., G. Ockert, S. Broemme, and A. Otto. 1991. On the clinical importance of Dientamoeba fragilis infections in childhood. J. Hyg. Epidemiol. Microbiol. Immunol.35:27-34.
    OpenUrlPubMed
  231. 231.↵
    Rabodonirina, M., M. Bertocchi, I. Desportes-Livage, L. Cotte, H. Levrey, M. A. Piens, G. Monneret, M. Celard, J. F. Mornex, and M. Mojon. 1996. Enterocytozoon bieneusi as a cause of chronic diarrhea in a heart-lung transplant recipient who was seronegative for human immunodeficiency virus. Clin. Infect. Dis.23:114-117.
    OpenUrlCrossRefPubMedWeb of Science
  232. 232.↵
    Reed, S. L., J. G. Curd, I. Gigli, F. D. Gillin, and A. I. Braude. 1986. Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica. J. Immunol.136:2265-2270.
    OpenUrlAbstract
  233. 233.↵
    Reed, S. L., J. A. Ember, D. S. Herdman, R. G. DiScipio, T. E. Hugli, and I. Gigli. 1995. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a. J. Immunol.155:266-274.
    OpenUrlAbstract
  234. 234.↵
    Resiere, D., J. M. Vantelon, P. Bouree, E. Chachaty, G. Nitenberg, and F. Blot. 2003. Isospora belli infection in a patient with non-Hodgkin's lymphoma. Clin. Microbiol. Infect.9:1065-1067.
    OpenUrlCrossRefPubMed
  235. 235.↵
    Ruttenberg, D., S. R. Ress, S. K. Price, A. H. Girdwood, and I. N. Marks. 1990. Common variable hypogammaglobulinemia. A case report. J. Clin. Gastroenterol.12:336-340.
    OpenUrl
  236. 236.↵
    Ryan, U., L. Xiao, C. Read, L. Zhou, A. A. Lal, and I. Pavlasek. 2003. Identification of novel Cryptosporidium genotypes from the Czech Republic. Appl. Environ. Microbiol.69:4302-4307.
    OpenUrlAbstract/FREE Full Text
  237. 237.↵
    Sadraei, J., M. A. Rizvi, and U. K. Baveja. 2005. Diarrhea, CD4+ cell counts and opportunistic protozoa in Indian HIV-infected patients. Parasitol. Res.97:270-273.
    OpenUrlCrossRefPubMedWeb of Science
  238. 238.↵
    Sanad, M. M., and J. S. Al-Malki. 2007. Cryptosporidiosis among immunocompromised patients in Saudi Arabia. J. Egypt. Soc. Parasitol.37:765-774.
    OpenUrlPubMed
  239. 239.↵
    Sanchez-Guillen Mdel, C., R. Perez-Fuentes, H. Salgado-Rosas, A. Ruiz-Arguelles, J. Ackers, A. Shire, and P. Talamas-Rohana. 2002. Differentiation of entamoeba histolytica/entamoeba dispar by PCR and their correlation with humoral and cellular immunity in individuals with clinical variants of amoebiasis. Am. J. Trop. Med. Hyg.66:731-737.
    OpenUrlAbstract
  240. 240.
    Sarfati, C., A. Bourgeois, J. Menotti, F. Liegeois, R. Moyou-Somo, E. Delaporte, F. Derouin, E. M. Ngole, and J. M. Molina. 2006. Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. Am. J. Trop. Med. Hyg.74:162-164.
    OpenUrlAbstract/FREE Full Text
  241. 241.↵
    Savioli, L., H. Smith, and A. Thompson. 2006. Giardia and Cryptosporidium join the ‘Neglected Diseases Initiative.’ Trends Parasitol.22:203-208.
    OpenUrlCrossRefPubMedWeb of Science
  242. 242.↵
    Schmidt, W., U. Wahnschaffe, M. Schafer, T. Zippel, M. Arvand, A. Meyerhans, E.-O. Riecken, and R. Ullrich. 2001. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy. Gastroenterology120:984-987.
    OpenUrlCrossRefPubMedWeb of Science
  243. 243.↵
    Seydel, K. B., E. Li, Z. Zhang, and S. L. Stanley, Jr. 1998. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. Gastroenterology115:1446-1453.
    OpenUrlCrossRefPubMed
  244. 244.↵
    Seyrafian, S., N. Pestehchian, M. Kerdegari, H. A. Yousefi, and B. Bastani. 2006. Prevalence rate of Cryptosporidium infection in hemodialysis patients in Iran. Hemodial Int.10:375-379.
    OpenUrlCrossRefPubMed
  245. 245.↵
    Shamsuzzaman, S. M., and Y. Hashiguchi. 2002. Thoracic amebiasis. Clin. Chest Med.23:479-492.
    OpenUrlCrossRefPubMedWeb of Science
  246. 246.↵
    Shetty, N., S. Nagpal, P. V. Rao, and H. Schroder. 1990. Detection of IgG, IgA, IgM and IgE antibodies in invasive amoebiasis in endemic areas. Scand. J. Infect. Dis.22:485-491.
    OpenUrlCrossRefPubMed
  247. 247.↵
    Shum, B. O., M. S. Rolph, and W. A. Sewell. 2008. Mechanisms in allergic airway inflammation-lessons from studies in the mouse. Expert Rev. Mol. Med.10:e15.
    OpenUrlCrossRefPubMed
  248. 248.↵
    Sing, A., K. Tybus, J. Heesemann, and A. Mathis. 2001. Molecular diagnosis of an Enterocytozoon bieneusi human genotype C infection in a moderately immunosuppressed human immunodeficiency virus seronegative liver-transplant recipient with severe chronic diarrhea. J. Clin. Microbiol.39:2371-2372.
    OpenUrlFREE Full Text
  249. 249.↵
    Smith, H. V., and G. D. Corcoran. 2004. New drugs and treatment for cryptosporidiosis. Curr. Opin. Infect. Dis.17:557-564.
    OpenUrlCrossRefPubMedWeb of Science
  250. 250.↵
    Som, I., A. Azam, A. Bhattacharya, and S. Bhattacharya. 2000. Inter- and intra-strain variation in the 5.8S ribosomal RNA and internal transcribed spacer sequences of Entamoeba histolytica and comparison with Entamoeba dispar, Entamoeba moshkovskii and Entamoeba invadens. Int. J. Parasitol.30:723-728.
    OpenUrlCrossRefPubMed
  251. 251.↵
    Stark, D., N. Beebe, D. Marriott, J. Ellis, and J. Harkness. 2005. Detection of Dientamoeba fragilis in fresh stool specimens using PCR. Int. J. Parasitol.35:57-62.
    OpenUrlCrossRefPubMedWeb of Science
  252. 252.
    Stark, D., N. Beebe, D. Marriott, J. Ellis, and J. Harkness. 2006. Evaluation of three diagnostic methods, including real-time PCR, for detection of Dientamoeba fragilis in stool specimens. J. Clin. Microbiol.44:232-235.
    OpenUrlAbstract/FREE Full Text
  253. 253.↵
    Stark, D., N. Beebe, D. Marriott, J. Ellis, and J. Harkness. 2005. Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population. J. Clin. Microbiol.43:2718-2723.
    OpenUrlAbstract/FREE Full Text
  254. 254.↵
    Stark, D., R. Fotedar, S. van Hal, N. Beebe, D. Marriott, J. T. Ellis, and J. Harkness. 2007. Prevalence of enteric protozoa in human immunodeficiency virus (HIV)-positive and HIV-negative men who have sex with men from Sydney, Australia. Am. J. Trop. Med. Hyg.76:549-552.
    OpenUrlAbstract/FREE Full Text
  255. 255.↵
    Stark, D., O. Phillips, D. Peckett, U. Munro, D. Marriott, J. Harkness, and J. Ellis. 2008. Gorillas are a host for Dientamoeba fragilis: an update on the life cycle and host distribution. Vet. Parasitol.151:21-26.
    OpenUrlCrossRefPubMed
  256. 256.↵
    Stark, D., S. van Hal, R. Fotedar, A. Butcher, D. Marriott, J. Ellis, and J. Harkness. 2008. Comparison of stool antigen detection kits to PCR for diagnosis of amebiasis. J. Clin. Microbiol.46:1678-1681.
    OpenUrlAbstract/FREE Full Text
  257. 257.↵
    Stark, D. J., N. Beebe, D. Marriott, J. T. Ellis, and J. Harkness. 2006. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol.22:92-96.
    OpenUrlCrossRefPubMedWeb of Science
  258. 258.↵
    Stauffer, W., M. Abd-Alla, and J. I. Ravdin. 2006. Prevalence and Incidence of Entamoeba histolytica Infection in South Africa and Egypt. Arch. Med. Res.37:265-268.
    OpenUrlCrossRef
  259. 259.↵
    Stauffer, W., and J. I. Ravdin. 2003. Entamoeba histolytica: an update. Curr. Opin. Infect. Dis.16:479-485.
    OpenUrlCrossRefPubMedWeb of Science
  260. 260.↵
    Stensvold, R., A. Brillowska-Dabrowska, H. V. Nielsen, and M. C. Arendrup. 2006. Detection of Blastocystis hominis in unpreserved stool specimens by using polymerase chain reaction. J. Parasitol.92:1081-1087.
    OpenUrlCrossRefPubMed
  261. 261.↵
    Stenzel, D. J., and P. F. Boreham. 1996. Blastocystis hominis revisited. Clin. Microbiol. Rev.9:563-584.
    OpenUrlAbstract/FREE Full Text
  262. 262.
    Reference deleted.
  263. 263.↵
    Sturdee, A. P., R. M. Chalmers, and S. A. Bull. 1999. Detection of Cryptosporidium oocysts in wild mammals of mainland Britain. Vet. Parasitol.80:273-280.
    OpenUrlCrossRefPubMedWeb of Science
  264. 264.↵
    Tan, K. S. 2004. Blastocystis in humans and animals: new insights using modern methodologies. Vet. Parasitol.126:121-144.
    OpenUrlCrossRefPubMedWeb of Science
  265. 265.↵
    Tanizaki, A., H. Yoshikawa, S. Iwatani, and I. Kimata. 2005. Infectivity of Blastocystis isolates from chickens, quails and geese in chickens. Parasitol. Res.96:57-61.
    OpenUrlCrossRefPubMed
  266. 266.↵
    ten Hove, R. J., L. van Lieshout, E. A. Brienen, M. A. Perez, and J. J. Verweij. 2008. Real-time polymerase chain reaction for detection of Isospora belli in stool samples. Diagn. Microbiol. Infect. Dis.61:280-283.
    OpenUrlCrossRefPubMed
  267. 267.↵
    Tilley, M., V. McDonald, and G. J. Bancroft. 1995. Resolution of cryptosporidial infection in mice correlates with parasite-specific lymphocyte proliferation associated with both Th1 and Th2 cytokine secretion. Parasite Immunol.17:459-464.
    OpenUrlPubMedWeb of Science
  268. 268.↵
    Tosoni, A., M. Nebuloni, A. Ferri, S. Bonetto, S. Antinori, M. Scaglia, L. Xiao, H. Moura, G. S. Visvesvara, L. Vago, and G. Costanzi. 2002. Disseminated microsporidiosis caused by Encephalitozoon cuniculi III (dog type) in an Italian AIDS patient: a retrospective study. Mod. Pathol.15:577-583.
    OpenUrlCrossRefPubMedWeb of Science
  269. 269.↵
    Tsai, J. J., H. Y. Sun, L. Y. Ke, K. S. Tsai, S. Y. Chang, S. M. Hsieh, C. F. Hsiao, J. H. Yen, C. C. Hung, and S. C. Chang. 2006. Higher seroprevalence of Entamoeba histolytica infection is associated with human immunodeficiency virus type 1 infection in Taiwan. Am. J. Trop. Med. Hyg.74:1016-1019.
    OpenUrlAbstract/FREE Full Text
  270. 270.↵
    Tungtrongchitr, A., S. Manatsathit, C. Kositchaiwat, J. Ongrotchanakun, N. Munkong, P. Chinabutr, S. Leelakusolvong, and W. Chaicumpa. 2004. Blastocystis hominis infection in irritable bowel syndrome patients. Southeast Asian J. Trop. Med. Public Health35:705-710.
    OpenUrlPubMed
  271. 271.↵
    Vandenberg, O., R. Peek, H. Souayah, A. Dediste, M. Buset, R. Scheen, P. Retore, G. Zissis, and T. van Gool. 2006. Clinical and microbiological features of dientamoebiasis in patients suspected of suffering from a parasitic gastrointestinal illness: a comparison of Dientamoeba fragilis and Giardia lamblia infections. Int. J. Infect. Dis.10:255-261.
    OpenUrlCrossRefPubMedWeb of Science
  272. 272.↵
    van Gool, T., and J. Dankert. 1995. Human microsporidiosis: clinical, diagnostic and therapeutic aspects of an increasing infection. Clin. Microbiol. Infect.1:75-85.
    OpenUrlPubMed
  273. 273.↵
    van Hal, S. J., K. Muthiah, G. Matthews, J. Harkness, D. Stark, D. Cooper, and D. Marriott. 2007. Declining incidence of intestinal microsporidiosis and reduction in AIDS-related mortality following introduction of HAART in Sydney, Australia. Trans. R. Soc. Trop. Med. Hyg.101:1096-1100.
    OpenUrlCrossRefPubMed
  274. 274.↵
    van Hal, S. J., D. J. Stark, R. Fotedar, D. Marriott, J. T. Ellis, and J. L. Harkness. 2007. Amoebiasis: current status in Australia. Med. J. Aust.186:412-416.
    OpenUrlPubMedWeb of Science
  275. 275.↵
    Verdier, R. I., D. W. Fitzgerald, W. D. J. Jr., and J. W. Pape. 2000. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann. Intern. Med.132:885-888.
    OpenUrlCrossRefPubMedWeb of Science
  276. 276.↵
    Verweij, J. J., J. Schinkel, D. Laeijendecker, M. A. van Rooyen, L. van Lieshout, and A. M. Polderman. 2003. Real-time PCR for the detection of Giardia lamblia. Mol. Cell Probes17:223-225.
    OpenUrlCrossRefPubMedWeb of Science
  277. 277.↵
    Villegas Gonzalez, J., A. Mercado Cruz, and L. Jasso Gutierrez. 1970. Cerebral amebiasis. Pathogenic hypothesis. Report of 4 new cases. Rev. Investig. Salud Publica30:165-184.
    OpenUrl
  278. 278.↵
    Visvesvara, G. S., A. J. da Silva, G. P. Croppo, N. J. Pieniazek, G. J. Leitch, D. Ferguson, H. de Moura, S. Wallace, S. B. Slemenda, I. Tyrrell, and et al. 1995. In vitro culture and serologic and molecular identification of Septata intestinalis isolated from urine of a patient with AIDS. J. Clin. Microbiol.33:930-936.
    OpenUrlAbstract/FREE Full Text
  279. 279.↵
    Weber, R., R. T. Bryan, D. A. Schwartz, and R. L. Owen. 1994. Human microsporidial infections. Clin. Microbiol. Rev.7:426-461.
    OpenUrlAbstract/FREE Full Text
  280. 280.↵
    Weber, R., B. Ledergerber, R. Zbinden, M. Altwegg, G. E. Pfyffer, M. A. Spycher, J. Briner, L. Kaiser, M. Opravil, C. Meyenberger, M. Flepp, et al. 1999. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Arch. Intern. Med.159:1473-1480.
    OpenUrlCrossRefPubMedWeb of Science
  281. 281.↵
    Webster, A. D. 1980. Giardiasis and immunodeficiency diseases. Trans. R. Soc. Trop. Med. Hyg.74:440-443.
    OpenUrlCrossRefPubMed
  282. 282.↵
    Weitzel, T., S. Dittrich, I. Mohl, E. Adusu, and T. Jelinek. 2006. Evaluation of seven commercial antigen detection tests for Giardia and Cryptosporidium in stool samples. Clin. Microbiol. Infect.12:656-659.
    OpenUrlCrossRefPubMed
  283. 283.↵
    Westerman, E. L., and R. P. Christensen. 1979. Chronic Isospora belli infection treated with co-trimoxazole. Ann. Intern. Med.91:413-414.
    OpenUrlPubMed
  284. 284.↵
    Windsor, J. J., and E. H. Johnson. 1999. More laboratories should test for Dientamoeba fragilis infection. BMJ318:735.
    OpenUrlFREE Full Text
  285. 285.↵
    Windsor, J. J., A. M. Rafay, A. K. Shenoy, and E. H. Johnson. 1998. Incidence of Dientamoeba fragilis in faecal samples submitted for routine microbiological analysis. Br J. Biomed. Sci.55:172-175.
    OpenUrlPubMedWeb of Science
  286. 286.↵
    Wolska-Kusnierz, B., A. Bajer, S. Caccio, E. Heropolitanska-Pliszka, E. Bernatowska, P. Socha, J. van Dongen, M. Bednarska, A. Paziewska, and E. Sinski. 2007. Cryptosporidium infection in patients with primary immunodeficiencies. J. Pediatr. Gastroenterol. Nutr.45:458-464.
    OpenUrlCrossRefPubMed
  287. 287.↵
    Yazar, S., O. Yaman, F. Demirtaçs, S. Yalçin, M. Yücesoy, and I. Sahin. 2002. Cyclospora cayetanensis associated with diarrhea in a patient with idiopathic compensated hepatic cirrhosis. Acta Gastroenterol. Belg.65:241-244.
    OpenUrlPubMed
  288. 288.↵
    Yusuf, T. E., and T. H. Baron. 2004. AIDS cholangiopathy. Curr. Treat. Options Gastroenterol.7:111-117.
    OpenUrlCrossRefPubMed
  289. 289.↵
    Zali, M. R., A. J. Mehr, M. Rezaian, A. R. Meamar, S. Vaziri, and M. Mohraz. 2004. Prevalence of intestinal parasitic pathogens among HIV-positive individuals in Iran. Jpn. J. Infect. Dis.57:268-270.
    OpenUrlPubMed
  290. 290.
    Reference deleted.
  291. 291.↵
    Zar, F. A., E. El-Bayoumi, and M. M. Yungbluth. 2001. Histologic proof of acalculous cholecystitis due to Cyclospora cayetanensis. Clin. Infect. Dis.33:140-141.
    OpenUrlCrossRef
  292. 292.↵
    Zardi, E. M., A. Picardi, and A. Afeltra. 2005. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy51:193-196.
    OpenUrlCrossRefPubMedWeb of Science
  293. 293.↵
    Zhu, G., M. J. Marchewka, J. G. Ennis, and J. S. Keithly. 1998. Direct isolation of DNA from patient stools for polymerase chain reaction detection of Cryptosporidium parvum. J. Infect. Dis.177:1443-1446.
    OpenUrlCrossRefPubMedWeb of Science
  294. 294.↵
    Zierdt, C. H., V. J. Gill, and W. S. Zierdt. 1993. Detection of microsporidian spores in clinical samples by indirect fluorescent-antibody assay using whole-cell antisera to Encephalitozoon cuniculi and Encephalitozoon hellem. J. Clin. Microbiol.31:3071-3074.
    OpenUrlAbstract/FREE Full Text
  295. 295.↵
    Zimmer, S. M., A. N. Schuetz, and C. Franco-Paredes. 2007. Efficacy of nitazoxanide for cyclosporiasis in patients with sulfa allergy. Clin. Infect. Dis.44:466-467.
    OpenUrlCrossRefPubMed

Author Bios

Embedded Image Damien Stark is a Senior Hospital Scientist in the Microbiology Department at St. Vincents Hospital, Sydney, and is also an Associate, Department of Medical and Molecular Biosciences, Institute for the Biotechnology of Infectious Disease, University of Technology, Sydney (UTS). His research interests include clinical, diagnostic, and molecular parasitology, with a special interest in all aspects of D. fragilis research.

Embedded Image Joel Barratt is a research assistant and Ph.D. student at the University of Technology, Sydney (UTS), working in collaboration with St. Vincent's hospital, under the supervision of Professor John Ellis and Dr. Damien Stark. Joel completed his honors degree at UTS under the supervision of Professor John Ellis on the protozoan parasite Neosporacaninum. Joel's current research focuses on human enteric protozoa, with a particular focus on the trichomonad parasite Dientamoebafragilis.

Embedded Image John L. Harkness graduated from Monash University medical school in Melbourne, Australia, in 1967. Training as a junior medical officer was at the Alfred Hospital in Melbourne, followed by training in pathology at the Alfred Hospital, Hammersmith Hospital, London, United Kingdom, and the Mayo Clinic, Rochester, NY. He was appointed Director of Microbiology at St. Vincent's Hospital, Sydney, Australia, in 1975. He is an Associate Professor in the Medical Faculty, University of NSW, and Adjunct Professor at the University of Technology in Sydney. He is actively involved in teaching medical undergraduates and postgraduates. He is interested in infections in the immunocompromised host, antimicrobial therapy, and parasitology. Research interests in the laboratory in particular are in parasitology and mycology.

Embedded Image Deborah J. E. Marriott graduated from the University of New South Wales Medical School in 1978 and was awarded FRACP in 1985 and FRCPA in 1986. She is an Associate Professor, School of Medicine, UNSW, and Adjunct Professor at the University of Technology, Sydney. Deborah has a long-standing interest in infections in immunocompromised patients and was a founding member and past president of the Australasian Society for HIV Medicine. She is active in clinical research, particularly mycology and parasitology, and is an enthusiastic teacher and clinician.

Embedded Image John Ellis completed a Ph.D. on leishmaniasis with Professor J. M. Crampton at the Liverpool School of Tropical Medicine in 1986, and subsequently did postdoctoral research on Eimeria vaccines at Houghton Poultry Research Station (with Dr. M. Elaine Rose and colleagues) and parasite phylogeny (with Professor A. M. Johnson at the Flinders University of South Australia). John was appointed to the academic staff of the University Technology Sydney in 1992 as a Lecturer in Microbiology. Over the last 19 years he has continued to study parasitic protozoa of both veterinary and medical importance. John Ellis is currently Professor of Molecular Biology, and his present research interests include development of vaccines and diagnostics for protozoal diseases of economic importance. He was awarded the degree of D.Sc. by Liverpool University in 2006 for his pioneering research on the biology of cyst-forming coccidia. He is a Fellow of the Royal Society for Tropical Medicine and Hygiene and a member of the Australian, British, and American Societies for Parasitology.

Embedded Image Sebastiaan J. van Hal graduated from University of Cape Town in South Africa with honors in 1996. He worked extensively in Africa and England before moving to Australia in 1999. While completing his training for the Fellowship of the Royal Australasian College of Physicians (ID) and for the Royal College of Pathologists of Australasia (Microbiology), he has focused on developing his interests in infections in the immunocompromised host. His laboratory research interests include exploring how a patient's immune status influences not only the clinical presentation but also the utility and development of laboratory tests. He currently is working as a full-time staff specialist in infectious diseases and microbiology at Liverpool Hospital, Sydney.

PreviousNext
Back to top
Download PDF
Citation Tools
Clinical Significance of Enteric Protozoa in the Immunosuppressed Human Population
D. Stark, J. L. N. Barratt, S. van Hal, D. Marriott, J. Harkness, J. T. Ellis
Clinical Microbiology Reviews Oct 2009, 22 (4) 634-650; DOI: 10.1128/CMR.00017-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Clinical Microbiology Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Significance of Enteric Protozoa in the Immunosuppressed Human Population
(Your Name) has forwarded a page to you from Clinical Microbiology Reviews
(Your Name) thought you would be interested in this article in Clinical Microbiology Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Significance of Enteric Protozoa in the Immunosuppressed Human Population
D. Stark, J. L. N. Barratt, S. van Hal, D. Marriott, J. Harkness, J. T. Ellis
Clinical Microbiology Reviews Oct 2009, 22 (4) 634-650; DOI: 10.1128/CMR.00017-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • SUMMARY
    • INTRODUCTION
    • IMMUNITY
    • OPPORTUNISTIC INFECTIONS
    • OTHER PATHOGENIC ENTERIC PARASITES
    • CONCLUSIONS
    • REFERENCES
    • Author Bios
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Immunocompromised Host
Intestinal Diseases, Parasitic
Opportunistic Infections
Protozoan Infections

Related Articles

Cited By...

About

  • About CMR
  • Editor in Chief
  • Editorial Board
  • Policies
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Ethics
  • Contact Us

Follow #ClinMicroRev

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0893-8512; Online ISSN: 1098-6618